

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 680 517 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:

12.11.1997 Bulletin 1997/46

(51) Int Cl.⁶: **C12Q 1/68**

// **C12N15/85**

(21) Application number: **94907826.5**

(86) International application number:
PCT/US94/00583

(22) Date of filing: **21.01.1994**

(87) International publication number:
WO 94/17208 (04.08.1994 Gazette 1994/18)

(54) **METHODS AND DIAGNOSTIC KITS UTILIZING MAMMALIAN STRESS PROMOTERS TO
DETERMINE TOXICITY OF A COMPOUND**

VERFAHREN UND DIAGNOSTISCHE KITS UNTER VERWENDUNG VON
SÄUGER-STRESSPROMOTOREN ZUR BESTIMMUNG DER TOXIZITÄT EINER VERBINDUNG

METHODES ET TROUSSES DE DIAGNOSTIC FAISANT APPEL AUX PROMOTEURS DE STRESS
DES MAMMIFERES POUR DETERMINER LA TOXICITE D'UN COMPOSE

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **21.01.1993 US 8896**

(43) Date of publication of application:
08.11.1995 Bulletin 1995/45

(73) Proprietors:
• **PRESIDENT AND FELLOWS OF HARVARD
COLLEGE**
Cambridge, Massachusetts 02138 (US)
• **XENOMETRIX, INC.**
Boulder, Colorado 80301 (US)

(72) Inventors:
• **FARR, Spencer B.**
Longmont, CO 80304 (US)

• **TODD, Marque D**
Westminster, CO 80021 (US)

(74) Representative: **VOSSIUS & PARTNER**
Postfach 86 07 67
81634 München (DE)

(56) References cited:
EP-A- 0 325 849 **EP-A- 0 516 443**
WO-A-90/10710 **WO-A-92/05286**
WO-A-94/01584

• **MOLECULAR & CELLULAR BIOLOGY**, vol. 2, no.
9, September 1982, Washington, DC (US);
GORMAN et al., pp. 1044-1051

Note. Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art

0 680 517 B1

Description

TECHNICAL FIELD OF INVENTION

5 This invention provides methods and diagnostic kits for identifying and characterizing toxic compounds. These methods and diagnostic kits measure transcription or translation levels from genes linked to native eukaryotic stress promoters, especially those of mammals. The kits and methods of this invention utilize at least one stress promoter from each of the following groups: redox stress, DNA stress, protein stress and energy/ionic stress. The invention also provides methods and diagnostic kits for identifying and characterizing compounds that are toxic to specific organs, 10 such as skin and the eye, as well as for each of the individual stresses indicated above. The methods and diagnostic kits of this invention yield information concerning the action of a compound on a subcellular level. This information may be utilized to design antitoxins to compounds found to be toxic and in active drug design.

BACKGROUND OF THE INVENTION

15 At least 55,000 chemicals are presently produced in the United States. Over 2,000 new chemicals are introduced into the market each year. Very few of these chemicals have been comprehensively tested for acute or chronic toxicity. For example, less than 1 percent of commercial chemicals have undergone complete health hazard assessment.

20 The Environmental Protection Agency ("EPA") has the authority to require toxicological testing of a chemical prior to commercial production, but that authority is rarely invoked. Less than 10 percent of new chemicals are subjected to detailed review by the EPA. In the interest of cost and speedy access to the market, the EPA often uses the toxicity of previously tested homologous compounds to gauge the toxicity of a new chemical.

25 The potential toxicity of new drugs is monitored by the Food and Drug Administration ("FDA"). For a New Drug Application (NDA), the FDA typically requires a large battery of toxicity, carcinogenicity, mutagenicity and reproduction/fertility tests in at least two species of live animals. These tests are required to last up to one year. A two year toxicity test in rats costs approximately \$800,000 [Casarett and Doull's Toxicology, 4th Edition, M. O. Amdur et al., eds. Pergamon Press, New York, New York, p. 37 (1991)].

30 Besides cost, animal testing also presents disadvantages in terms of time, animal suffering and -accuracy. Typical toxicity tests are divided into three stages: acute, short term and long term. Acute tests, which determine the LD₅₀ of a compound (the dose at which 50% of test animals are killed), require some 60-100 animals and a battery of tests for determining LD₅₀, dose-response curves and for monitoring clinical end points, other than death. Short term tests usually involve at least 24 dogs and 90 rats and last from 90 days in rats to 6-24 months in dogs. Body weight, food consumption, blood, urine and tissue samples are frequently measured in the short-term tests. In addition, dead animals are subjected to post-mortem examinations. Long term tests are similar to short term tests, but last 2 years in rats and 35 up to 7 years in dogs or monkeys.

40 Animal testing has come under criticism by animal rights activists and the general public because of the severe suffering inflicted on the animals. Moreover, recent evidence calls into question the accuracy of animal testing. For example, variables, such as animal diet, may impair the predictability of animal tests in determining carcinogenic properties [P. H. Abelson, "Diet and Cancer in Humans and Rodents", *Science*, 255, p. 141 (1992)]. And prior determinations on dioxin toxicity, based on guinea pig testing, are now being reevaluated [B. J. Culliton, "US Government Orders New Look At Dioxin", *Nature*, 352, p. 753 (1991); L. Roberts, "More Pieces in the Dioxin Puzzle", *Research News*, October, 1991, p. 377]. It is therefore apparent that there is an urgent need for a quick, inexpensive and reliable alternative to toxicity testing in animals.

45 Several short-term alternative tests are available. For example, the Ames Assay detects carcinogens which cause genetic reversion of mutant strains of *Salmonella typhimurium*. However, the Ames Assay cannot detect either non-mutagenic carcinogens or non-carcinogenic toxins. The yeast carcinogen assay system described in United States patent 4,997,757 overcomes some of the drawbacks of the Ames Assay, but is still not able to detect non-carcinogenic toxins. Both of these assays are designed to detect alterations and mutations at the DNA level only. Therefore, those prior art tests cannot detect direct damage to proteins or lipid membranes, nor inhibitors of DNA synthesis. Moreover, 50 those prior art tests cannot provide information as to how a mutagen or toxin exerts its effect.

WO 90/10710 describes the use of a TNF, IL-1 α or IL-1 β fused to a reporter gene to detect bacterial pyrogens. However, the disclosed assay is limited in that it detects only a particular stress (bacterial pyrogens) and yields no qualitative information about how the pyrogen exerts its toxic effect.

55 In Applicant's document WO-A-9 401 584 an assay system is described which utilizes a reporter gene fused to bacterial stress promoters to determine and characterize the toxicity of a compound. This assay is able to detect damage to proteins or lipid membranes and inhibition of DNA synthesis. Thus, this assay provides for the identification of non-carcinogenic toxins. Unfortunately, the correlation between bacterial toxicity and toxicity to mammals and other higher eukaryotes has certain limitations and may not be an accurate measure of toxicity in higher animals.

Therefore, there is still a need for an assay that has the time and cost-saving features of the bacterial stress assay, but is based on a eukaryotic cell.

SUMMARY OF THE INVENTION

Applicant has fulfilled this need by providing an *in vitro* diagnostic kit and assay method which identify and characterize the cellular and subcellular effect of a potential toxin on an animal cell. These kits and methods employ the native stress promoters of eukaryotic cells, preferably mammalian cells, and measure the level of transcription or translation of a gene which is operatively linked thereto. Depending upon the choice of stress promoters used, the kits and methods of this invention may be designed to identify and characterize compounds that are toxic to the whole animal or to specific organs of that animal.

In one embodiment, the kits and methods of this invention characterize the toxicity of a compound by determining the level of transcription of various stress genes present in a eukaryotic cell. These kits and methods employ oligonucleotides that are complementary or homologous to at least a portion of various stress gene messenger RNAs to detect transcription of those genes in the cell. In this embodiment a single cell is effectively an *in vivo* diagnostic reagent for determining what particular stress a given compound induces.

In another embodiment, each of a plurality of similar eukaryotic cells harbors a different stress promoter operatively linked to a reporter gene. By exposing each cell separately to a compound and measuring the expression of the reporter gene product, the toxicity of that compound may be characterized.

The kits and methods of this invention are optimally designed to determine the toxicity of a compound in a matter of days, rather than the months or years required for animal testing. Furthermore, the kits of this invention achieve these results for a fraction of the cost of animal testing and without the objectionable consequences to live animals. And, the diagnostic kits and methods of this invention yield direct information about the nature of a toxin's action on mammalian cells -- something that the prior art short-term assays fail to do.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of tetrachlorodibenzo-*p*-dioxin (TCDD).

Figure 2 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of 3-methyl cholanthrene (3-MC).

Figure 3 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of benzo[a]pyrene.

Figure 4 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of cadmium sulfate.

Figure 5 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of dimethyl sulfoxide (DMSO).

Figure 6 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of ethanol.

Figure 7 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of methapyrilene hydrochloride.

Figure 8 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of methyl methanesulfonic acid (MMS).

Figure 9 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of sodium arsenate.

Figure 10 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of phorbol 12-acetate-13-myristate (PMA).

Figure 11 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of retinoic acid.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the terms "stress" and "toxicity" are used interchangeably and refer to the disturbance of the biochemical and biophysical homeostasis of the cell.

The term "redox stress", as used throughout this application, refers to conditions which vary from the normal reduction/oxidation potential ("redox") state of the cell. Redox stress includes increased levels of superoxides radicals, increased levels of peroxides -- both hydrogen peroxide and organic peroxides --, decreased levels of glutathione and any other conditions which alter the redox potential of the cell, such as exposure to strong reducing agents, some

aromatic hydrocarbons, electrophilic compounds, aldehydes, intracellular thiols, steroids, methyl cholanthrene, phenobarbital and CCl_4 . The term also includes any additional conditions which cause proliferation of peroxisomes.

The term "DNA stress", as used herein, refers to alterations to deoxyribonucleic acid or to precursor nucleotides. For example, DNA stress includes, but is not limited to, DNA strand breaks, DNA strand cross-linking, exposure to DNA intercalating agents, both increased and decreased superhelicity, oxidative DNA damage, DNA alkylation, oxidation of nucleoside triphosphates and alkylation of nucleoside triphosphates. The term also includes inhibition of DNA synthesis and replication and inhibition of mitosis or meiosis. And the term includes conditions caused by exposure to growth factors, interferons, tumor promoters, tumor necrosis factor, phorbol esters, hydrophobic cytotoxic drugs, inflammatory agents, mitogens, carcinogens, X-rays, UV radiation and dimethylnitrosamines.

"Protein stress", as used throughout the application, refers to alterations to proteins or individual amino acids and inhibition of enzyme functions, as well as perturbations of intracellular transport of proteins. The term includes, but is not limited to, denaturation of proteins, misfolding of proteins, chelation of protein cofactors, cross-linking of proteins, both oxygen-dependent and -independent oxidation of inter- and intra-chain bonds, such as disulfide bonds, alkylation of proteins, oxidation of individual amino acids and protein damage caused by exposure to heavy metals, such as cadmium and heat.

I use the term "energy/ionic stress" to encompass conditions which affect ATP levels in the cell or ionic gradients across a cell membrane. Examples of energy stress are forced anaerobic metabolism in the presence of oxygen, perturbations of electron transport, exposure to uncoupling agents, membrane depolarization, osmotic shock, exposure to ions, such as Ca^{2+} , exposure to high levels of cAMP and exposure to ethanol.

The term "cell surface receptor-mediated stress" refers to those conditions which alter the transcription level of genes whose expression is regulated by the interaction of a cell surface receptor with a ligand. Examples of such stress include exposure of the skin, eyes or mucous membranes to irritants, allergens or inflammatory compounds.

The term "stress promoter induction" refers to conditions which increase the level of expression of a gene operably linked to a native stress promoter or a recombinantly derived stress promoter which contains a response element. The term "operative linkage", "operatively linked" or "operably linked" refers to the positioning of the promoter relative to the gene such that transcription of the gene is regulated by the promoter. The term encompasses both recombinant constructs as well as the structure of a naturally occurring promoter and its associated gene.

The term "determining and characterizing the toxicity of a compound" includes identifying a compound as a toxin and elucidating its mechanism of action within the cell.

The term "nucleic acid sequences" as used in this application, includes RNA, single or doublestranded cDNA or portions thereof, single or doublestranded genomic DNA or portions thereof, or single or double stranded synthetic oligonucleotides.

Whereas every gene is controlled by a unique promoter, genes which respond to identical stresses contain a common response element within their promoters. Accordingly, the same response element is responsible for inducing expression of a family of genes upon exposure to a certain stress. When isolated and operably linked to a minimal promoter and a structural gene, the resulting construct functions like a stress promoter. This is particularly useful in dissecting a native stress promoter that responds to multiple stresses into its component parts.

Individual cells respond to toxic stimuli, in part, by activating specific genes whose protein products detoxify the stimuli or repair damage caused thereby. Eukaryotic cells have large number of genetic and biochemical responses to damage and stress. At least 50 different mammalian stress genes have already been isolated and characterized. These genes are induced by a variety of chemical and physical stresses or cellular damage.

Among the chemical stresses which induce one or more of these identified genes are exposure of the cell to mercury, heavy metals, nitroxides, aromatic hydrocarbons, acidity, basicity, alkylating agents, peroxidizing agents, cross-linking agents, ionophores, redox active agents, electrophilic compounds, inflammatory agents, hydrophobic cytotoxic drugs, ethanol, steroids, uncoupling agents, tumor promoters and cellular factors, such as tumor necrosis factor, growth factors and interferon. Physical stresses include exposure to UV radiation, heat or X-rays.

Examples of cellular damage which induce these identified genes are lipid oxidation, peroxisome proliferation, DNA strand breaks, DNA alkylation, DNA cross-linking, DNA oxidation, osmotic imbalance, protein oxidation, protein misfolding, protein alkylation, ATP depletion, membrane permeabilization, glutathione depletion and alterations in signal transduction. Many more stress genes are believed to exist. The identification and characterization of these additional stress genes is highly desirable in understanding what effects various chemical stresses have on the cell.

The present invention provides diagnostic kits and methods for determining and characterizing the toxicity of a compound in terms of the type of damage it causes within the cell, i.e., DNA damage, protein damage, redox damage, energy damage, ionic damage, etc. According to one embodiment, each diagnostic kit of this invention comprises a plurality of eukaryotic cells, each of which harbors at least one promoter or one promoter element which responds to stress. The plurality of cells, in toto, must comprise at least one promoter or promoter element which responds to each of the aforementioned types of stresses -- redox, DNA, protein and energy/ionic -- operably linked to a gene encoding a detectable product.

According to one embodiment, the plurality of cells in this kit are actually a single cell line, wherein each cell contains all of the different types of stress promoters and wherein each of those promoters is activated upon exposure to the appropriate stress. In this embodiment, the genes operatively linked to the stress promoters are most preferably the native stress genes. In this manner no genetic manipulation need be carried out on the cells prior to running an assay. In this preferred embodiment, the kits further comprise oligonucleotides or cDNAs which are complementary to at least a portion of either the coding or non-coding strand of the genes under control of the specific stress promoters. The oligonucleotides are used to detect and quantify the mRNA transcripts of those genes or the cDNA complements thereof, either of which may be the detectable product in this embodiment.

It should be noted that although all eukaryotic cells contain numerous stress promoters within their genomes, some of those promoters may or may not be activatable upon exposure to the proper stress. This is especially true in higher eukaryotes, such as mammals. Those cell lines whose stress promoters do respond to almost all of the appropriate stresses are preferred in the kits of this invention. These include primary tissue from mammalian liver, heart, lung, kidney, brain, or other organ, as well as mammalian derived cell lines established from these tissues available from American Type Culture Collection (ATCC, Rockville, MD). More preferred are HepG2 cells, HeLa cells and WIL-2 cells. Most preferred are HepG2 cells.

The oligonucleotides employed in the above diagnostic kits and methods of this invention are chosen based upon their ability to specifically hybridize under relatively high stringency conditions to either the transcription product of the gene operatively linked to the various stress promoters or its complement (i.e., a single-stranded cDNA reverse transcribed from that mRNA). The choice of utilizing complementary or homologous oligonucleotides depends upon the method used for detecting the transcription products. These various methods are described later in the application.

Because the DNA sequences of many mammalian stress genes are known, hybridizable oligonucleotides are easily constructed. It should be noted that 100% homology or complementarity between the oligonucleotide and the stress gene mRNA is not required. This is because the oligonucleotide may be designed based upon the sequence of a stress gene from a species different from the source of the cells utilized in the kits and methods of this invention.

While it is expected that similar stress genes from different mammalian species will be closely related, the transcripts from those genes will most likely not have identical nucleotide sequences. Accordingly, the oligonucleotides utilized in the kits and methods of this invention are preferably at least 95% homologous or complementary. Preferably, the oligonucleotides are between 20 and 500 base pairs long. Most preferably, the oligonucleotides are between 50 and 100 base pairs.

More preferably, the oligonucleotides are synthesized using an oligonucleotide synthesizer, optionally followed by polymerase chain reaction ("PCR"). In this procedure, an oligonucleotide having a sequence identical to a portion of either the template strand or the non-coding strand and within the coding region of a known, sequenced stress gene is synthesized. If PCR is to be used to increase the quantity of oligonucleotide, the oligonucleotide is synthesized with an additional 6 to 12 nucleotides at each end. Those extra nucleotides serve as targets for complementary primers in a PCR reaction. Preferably the extra nucleotides at each end are complementary to one another. This allows a single primer to prime off of both the original oligonucleotide and the PCR product thereof. Most preferably, the extra nucleotides at each end are complementary homohexamers, i.e., AAAAAA at one end and TTTTTT at the other.

During PCR, one or more labeled nucleotides are preferably included in the polymerase reaction. Preferably the label is ³²P, biotin or a fluorescent marker. This results in a labelled product that can be used directly to detect the level of transcription product. The advantage of this mixed oligonucleotide synthesizer/PCR technique is that microgram quantities of labelled oligonucleotide can be produced in a single procedure. The resulting oligonucleotides may optionally be biotinylated following synthesis and purification.

If the oligonucleotide is used to detect cDNA reverse transcripts of the transcription product, it is preferable that they not be labelled. In this embodiment, it is preferred that the label be incorporated into the cDNA, rather than the oligonucleotide.

The design of appropriate oligonucleotide probes for use in the kits and methods of this invention is relatively straightforward. Obviously, they should have high sequence similarity or complementarity to the stress gene mRNA to which they are designed to hybridize. The oligonucleotides in any particular kit should also have approximately the same melting temperature (T_m) so that a single warming apparatus (such as a water bath) may be utilized when carrying out hybridization and subsequent washing steps. Preferably the oligonucleotides are designed to have a T_m of greater than 70°C in 0.2X SSC. To determine which portions of the coding regions of the stress gene to use in designing oligonucleotide probes, one may utilize a commercially available computer program, such as OLIGO (National Biosciences, Plymouth, MN).

According to another embodiment, each of the plurality of eukaryotic cells in the diagnostic kit of this invention harbors a stress promoter or a stress response element which is operatively linked to a heterologous gene encoding a detectable product. In this embodiment, it is preferable that the same heterologous gene be linked to the various stress promoters or response elements in the kit. In this manner, only a single assay need be performed to detect induction of any of the stress promoters and stress response elements. It is also preferable that each cell within the

kit contains only a single stress promoter or response element/heterologous gene construct. Thus, the expression of the detectable product in any given cell in the kit can be specifically correlated to the induction of a single stress promoter or response element.

The diagnostic kits and methods of this invention employ a plurality of eukaryotic cells, which, in toto, comprise promoters or response elements that respond to each of: redox stress, DNA stress, protein stress and energy stress. The preferred promoters and response elements of this invention for use with mammalian cells are listed below in Table 1.

TABLE 1

Preferred Mammalian Stress Promoters

Promoter	Redox	DNA	Protein	Energy/ Ionic
CYP1A1	X			
GST Ya	X	X		
GADD45		X		
GRP78		X	X	X
JUN	X	X	X	
FOS		X	X	X

Table 1 (cont'd)

Promoter	Redox	DNA	Protein	Energy/ Ionic
XHF		X		
HSP70			X	
MT IIA	X		X	
GADD153		X		
ALDH 1	X			
HMO	X	X		
CRE				X
XRE	X			
NFkBRE	X	X		
RARE	X			
ThRE	X			
PPRE	X			
TRE		X		
ERE	X			
p53RE		X		

Preferably, the promoters or response elements which respond to redox stress in the methods and kits of this invention are selected from the promoters of the CYP1A1, GST Ya, JUN, ALDH1 and HMO genes and the XRE, NFkBRE, PPRE, RARE, ERE, and ThRE response elements.

The CYP1A1 gene encodes cytochrome P450 1A1, an enzyme involved in the metabolism of polycyclic aromatic hydrocarbons, such as benzo(a)pyrene. The gene is inducible by aromatic hydrocarbons, plant flavones and also by tetrachlorodibenzo-p-dioxin (TCDD), one of the most potent teratogens and tumor promoters [L. A. Neuhold et al., *Mol. Cell. Biol.*, 9, pp. 2378-2386 (1989); Y. Fujii-Kuriyama et al., *The FASEB J.*, 6, pp. 706-710 (1992); D. W. Nebert et al., *Env. Health Perspec.*, pp. 13-25 (1990); R. A. Dixon et al., *Biol. Rev.*, 61, pp. 239-241 (1986)]. The sequence of this gene is described in K. Sogawa et al., *Proc. Natl. Acad. Sci. USA*, pp. 8044-8048 (1986).

The GST Ya gene encodes the glutathione S-transferase Ya subunit, a unique xenobiotic-responsive element. The redox stress-sensitive portion of the GST Ya promoter is strongly induced by electrophilic herbicides, insecticides and planar aromatic hydrocarbons such as β -naphthoflavone and 3-methylcholanthrene [T. H. Rushmore et al., *Proc. Natl. Acad. Sci. USA*, 87, pp. 3826-3830 (1990)]. The sequence of this gene is described in T. H. Rushmore et al., *supra*.

The JUN oncogene codes for c-jun which participates in the formation of the AP-1 complex — a transcriptional activator. Redox stresses which activate the JUN gene are superoxide radicals and UVA radiation. The sequence of this gene is described in R. De Groot et al., *EMBO J.*, 10, pp. 2523-2532 (1991).

The ALDH 2 gene encodes aldehyde dehydrogenase and is induced by aldehydes and peroxisome proliferators [D. W. Nebert, *Env. Health Persp.*, 88, pp. 13-25 (1990)]. The sequence of that gene is described in L.C. Hsu et al., *Proc. Natl. Acad. Sci. USA*, 82, pp. 3771-3775 (1985).

The HMO gene codes for heme oxygenase. The promoter is induced by the following redox stresses: oxidative stress, hydrogen peroxide, and sodium arsenite [S. T. Keyse and R. M. Tyrell, *Proc. Natl. Acad. Sci. USA*, 86, pp. 99-103 (1989)]. The sequence of this gene is described in that document.

The XRE is a redox stress response element. It responds to xenobiotics, such as aromatic hydrocarbons [T. H. Rushmore et al., *Proc. Natl. Acad. Sci. USA*, 87, pp. 3826-3830 (1990)]. The sequence of this response element is described in that document.

NFkBRE is a redox stress response element which encodes a transcription factor that is activated by intracellular thiols [R. Schreck et al., *EMBO J.*, 10, pp. 2247-2253 (1991); B. Nelson et al., *Molec. Cell. Biol.*, 8, pp. 3526-3531 (1988)]. It also responds to DNA stress. The sequence of this response element is described in K. Leung and G. J. Nabel, *Nature*, 333, pp. 776-778 (1988).

PPRE is the peroxisome proliferation response PPRE is the peroxisome proliferation response element. It is a redox stress responsive element that is induced by peroxisome proliferators [C. Dreyer et al., *Cell*, 68, pp. 879-887 (1992)]. The sequence of this response element is described in that document.

RARE is the retinoic acid response element. It is a redox stress-sensitive response element that responds to the steroid hormone retinoic acid and its analogs [H. de The et al., *Nature*, 343, pp. 177-180 (1990)].

ERE is the estrogen response element. It responds to redox stress that is induced by estrogenic compounds. The sequence of the ERE is described in V. Kumar et al., *Cell*, 55, pp. 145-156 (1988).

ThRE is the thyroid hormone response element. It responds to redox stress that is induced by thyroid hormone and its analogs. The sequence of the ThRE is described in M. Beato, *Cell*, 56, pp. 335-344 (1989).

Other promoters and response elements which respond to redox and can be utilized in the kits and methods of this invention may be selected from those listed in Table 2, below. In the brief description of each of these genes and response elements that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets.

UGT encodes a UDP-glucuronosyl transferase and its redox response is induced by 3-methyl cholanthrene [T. Iyanagi et al. *J. Biol. Chem.*, 261, pp. 15607-14 (1986)]. CYP11B2 encodes a cytochrome P450 whose redox response is induced by steroids [T. Kawamoto et al., *Proc. Natl. Acad. Sci. USA*, 89, pp. 1458-62 (1992)]. Cu,ZnSOD encodes a superoxide dismutase that is induced by copper- and zinc-catalyzed superoxide formation [E. Danciger et al., *Proc. Natl. Acad. Sci. USA*, 83, pp. 3619-23 (1986)]. The MnSOD gene encodes a superoxide dismutase which can be activated by tumor necrosis factor, interleukin-2 and lipopolysaccharides [M. K. St. Clair and J. C. Holland, *Cancer Res.*, 51, pp. 939-943 (1991)]. ADPRT encodes a ribosyl transferase and is induced by oxidative stress. GP encodes glutathione peroxidase and its redox response is induced by peroxides [S. Chada, *Genomics*, 6, pp. 268-71 (1990)]. FAOxase encodes fatty acyl-CoA oxidase and is induced by peroxisome proliferators [S. Miyazawa et al., *J. Biol. Chem.*, 262, pp. 8131-37 (1987)]. BE encodes a peroxisomal enoyl-CoA hydratase/3-hydroxyacyl CoA dehydrogenase bifunctional enzyme and is induced by peroxisome proliferators [J. K. Reddy et al., *Proc. Natl. Acad. Sci. USA*, 83, pp. 1747-51 (1986)]. PPAR encodes a peroxisome proliferator-activated receptor and is induced by peroxisome proliferators [C. Dreyer et al., *Cell*, 68, pp. 879-87 (1992)]. EH encodes an epoxide hydrolase which responds to redox stress caused by phenobarbital [R. K. Skoda et al., *J. Biol. Chem.*, 263, pp. 1549-54 (1988)]. CYP2B2 [J. S. Miles et al., *Nucl. Acids Res.*, 16, pp. 5783-95 (1988)], CYP2E1 [J. E. Freeman et al., *Biochem. J.*, 28, pp. 689-95 (1992)] and CYP3A3 [N. K. Spurr et al., GenBank Accession number X12387] encode three different cytochrome P450s. They are

responsive to redox stress caused by phenobarbital (2B2), CCl₄ (2E1), and aflatoxin, cyclosporin, testosterone and nifedipine (3A3), respectively. The P450b gene encodes the cytochrome P450b which is induced by phenobarbital [C. M. Giachelli et al., *J. Biol. Chem.*, 264, pp. 7046-7053 (1989)]. The P450d gene encodes cytochrome P450d, which is induced by polycyclic aromatic hydrocarbons, isosafrole, and 3-amino-1-5H-pyrido[4,3-b]indole (Trp-P-2) [K. Sogawa et al., *J. Biol. Chem.*, 260, pp. 5026-5032 (1985)]. PPa encodes a poly (ADP-ribose) polymerase and has a redox stress-sensitive component which responds to lipid peroxidation and oxidative stress [K. Uchida et al., *Biochem. Biophys. Res. Comm.*, 148, pp. 617-22 (1987)]. PKC encodes protein kinase C and its redox stress-sensitive component is induced by lipid peroxidation. ALDH1 encodes another aldehyde dehydrogenase that is induced by aldehydes and peroxisome proliferators [L.C. Hsu et al., *Proc. Natl. Acad. Sci. USA*, 82, pp. 3771-75 (1985)]. The NMO1 gene encodes the NAD(P)H menadione oxidoreductase and is induced by various xenobiotics including planar aromatic compounds, azo dyes and phenolic antioxidants [L. V. Favreau and C. B. Pickett, *J. Biol. Chem.*, 266, pp. 4556-4561 (1991)]. The GST2 gene encodes glutathione S-transferase-2 and responds to similar redox stresses as GST Ya [P. G. Board et al., *Proc. Natl. Acad. Sci. USA*, 84, pp. 2377-81 (1987)]. The GAPDH gene encodes glyceraldehyde-3-phosphate dehydrogenase [L. Ercolani et al., *J. Biol. Chem.*, 263, pp. 15335-41 (1988)]. The NQO gene encodes NAD(P)H quinone oxidoreductase and responds to the same redox stresses as NMO [A. K. Jaiswal, *Biochemistry*, 30, pp. 10647-53 (1991)].

The promoters and response elements which respond to DNA stress that are useful in the methods and kits of this invention are preferably selected from the promoters of the GST Ya, GADD45, JUN, FOS, XHF and GADD153 genes and the TRE and p53RE response elements.

The GST Ya gene is described above. Its DNA stress-sensitive component is induced by alkylated DNA.

The GADD45 gene encodes a growth arrest and DNA damage responsive protein. The GADD45 gene is induced by UV irradiation, X-rays, and the DNA damaging agent, methyl methane sulfonate (MMS). This gene is described in Q. Zhan et al., *Mol. Cell Biol.*, 13, pp. 4242-50 (1993).

The JUN gene has a DNA stress-sensitive component that is induced by UVA radiation, tumor promoters and growth factors.

The FOS gene encodes the oncogene c-fos. The DNA stress-sensitive components of its promoter are induced by tumor promoters and growth factors [E. M. Haliday, *EMBO J.*, 10, pp. 109-115 (1991)]. The sequence of this gene is described in F. van Straaten et al., *Proc. Natl. Acad. Sci. USA*, 80, pp. 3183-3187 (1983).

The XHF gene codes for collagenase and is activated by mitogenesis, inflammatory agents, UV radiation, and also in response to the tumor promoter, 12-O-tetradecanoyl-phorbol-13-acetate (TPA). The sequence of this gene is described in P. Angel et al., *Mol. Cell Biol.*, 7, pp. 2256-2266 (1987).

The GADD153 gene is expressed in response to growth arresting signals and DNA damaging agents [J. D. Luethy and N. J. Holbrook, *Cancer Res.*, 52, pp. 5-10 (1992)]. The sequence of this gene is described in A.J. Fornace et al., *Mol. Cell Biol.*, 9, pp. 4196-4203 (1989).

TRE is the TPA response element. It responds to DNA stress induced by phorbol esters. The sequence of TRE is described in P. Angel et al., *Cell*, 55, pp. 875-85 (1988).

p53RE is the p53 response element. It is responsive to DNA stress and is induced by X-rays and MMS. The sequence of the p53RE is described in Q. Zahn et al., *Mol. Cell Biol.*, 13, pp. 4242-4250 (1993).

Other promoters which respond to DNA stress and are useful in the methods and kits of this invention are listed in Table 2, below. In the brief description of each of these gene that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets.

The EGR-1 gene encodes an early growth response factor and is induced by mitogenesis and phosphatase inhibitors [S. V. Suggs, *Nucl. Acids Res.*, 18, pp. 4283-89 (1990)]. The GAS 2,3 gene is a gene which responds to growth arrest [C. Schneider et al., *Cell*, 54, pp. 787-793 (1988)]. The MGMT encodes an O-6-methylguanine methyltransferase and is induced by alkylated DNA [K. Tano et al., *Proc. Natl. Acad. Sci. USA*, 87, pp. 686-90 (1990)]. DNA Pol encodes DNA polymerase A and is induced by mitogens. TK (which encodes thymidine kinase) [H. D. Bradshaw Jr. et al., *Mol. Cell Biol.*, 4, pp. 2316-20 (1984)], DHFR (which encodes dihydrofolate reductase) [C. Morandi, *J. Mol. Biol.*, 156, pp. 583-607 (1982)] and PCNA (which encodes proliferating cell nuclear antigen) [D. Jaskulski et al., *J. Biol. Chem.*, 263, pp. 10175-79 (1988)] each are induced by cell proliferation. PGHS encodes prostaglandin endoperoxidase synthase and is induced by mitogens [S. A. Kraemer et al., *Arch. Biochem. Biophys.*, 293, pp. 391-400 (1992)]. LOX encodes a 5/12-lipoxygenase and is activated by exposure to tumor necrosis factor [P. A. Dixon et al., *Proc. Natl. Acad. Sci. USA*, 85, pp. 416-20 (1988)]. ISG15, which is interferon-stimulated gene, is induced by α -interferon [N. Reich et al., *Proc. Natl. Acad. Sci. USA*, 84, pp. 6394-98 (1987)]. 2'-5' AS, which encodes 2'-5' oligoadenylate synthetase, is induced by β -interferon [M. Walthelet et al., *FEBS Lett.*, 196, pp. 113-20 (1986)]. EH, which is discussed above, contains a DNA stress-sensitive component which is activated by carcinogens. CYP2E1 contains a DNA stress-sensitive element which responds to dimethylnitrosamine. TPO1 and TPO2 encode topoisomerases and are induced by DNA strand breaks and agents which cause promoter recombination [P. D'arpa et al., *Proc. Natl. Acad. Sci. USA*, 85, pp. 2543-47 (1988); M. Tsai-Pflufelder et al., *Proc. Natl. Acad. Sci. USA*, 85, pp. 7177-81 (1988)]. PPa, which was also discussed above,

responds to DNA stress caused by DNA damage. DRA encodes HLA class II and is induced by interferon gamma [A. J. Korman et al., Proc. Natl. Acad. Sci. USA, 79, pp. 6013-17 (1982); D. A. Shackelford et al., Immunol. Rev., 66, pp. 133-187 (1982)]. The MnSOD promoter, which is described above, also contains a DNA stress-responsive element that is induced by tumor necrosis factor. The MDR-1 gene encodes a protein which imparts multi-drug resistance and is mainly induced by hydrophobic cytotoxic drugs [J. A. Silverman et al., Gene, 106, pp. 229-236 (1991)]. The beta-pol gene encodes the DNA repair enzyme DNA polymerase beta and responds to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), mechlorethamine hydrochloride (HN2), and cis-platinum(II) diamine dichloride (cis-Pt) [S. G. Widen et al., J. Biol. Chem., 263, pp. 16992-98 (1988)]. The stromelysin-1 gene encodes a protein that is induced by phorbol esters, such as PMA [K. L. Sirum et al., Biochemistry, 28, pp. 8691-98 (1989)]. The PCNA gene encodes proliferating cell nuclear antigen which is induced by tumor promoters [S. Trivali et al., J. Biol. Chem., 264, pp. 7466-72 (1989)].

Promoters which respond to protein stress useful in the methods and kits of this invention are preferably selected from GRP78, JUN, FOS, HSP70 and MTIIA.

The GRP78 gene encodes a 78-kDa protein that is a major endoplasmic reticulum component. GRP78 is induced by misfolded proteins and glycosylation blocks [S. K. Wooden et al., Mol. Cell Biol., 11, pp. 5612-23 (1991)]. The sequence of this gene is described in E. Resendez et al., Mol. Cell Biol., 5, pp. 1212-19 (1985).

JUN and FOS, which are described above, both contain protein stress-responsive elements that are induced by heat.

The HSP70 gene encodes the heat shock protein 70 and is induced by heat, denatured proteins, amino acid analogues, heavy metals, anoxia and inhibitors of energy metabolism [D. D. Mosser et al., Mol. Cell Biol., 8, pp. 4736-44 (1988)]. The sequence of this gene is described in C. Hunt and R. I. Morimoto, Proc. Natl. Acad. Sci. USA, 82, pp. 6455-59 (1985).

MT IIA, which encodes metallothioneine IIA, is induced by heavy metals and glucocorticoids [M. Karin et al., Nature, 299, pp. 797-802 (1982)]. The sequence of that gene is described in the above reference.

Other promoters which may be employed in the kits and methods of this invention to detect protein stress may be selected from those promoters listed in Table 2, below, which respond to protein stress. In the brief description of each of these genes that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets.

MT 1A [R. I. Richards et al., Cell, 37, pp. 263-72 (1984)] and MT III [R. D. Palmiter et al., Proc. Natl. Acad. Sci. USA, 89, pp. 6333-37 (1992)] each encode a metallothionein gene that is induced by the heavy metal, cadmium. GP contains an element that responds to the protein damaging heavy metal, selenium.

The preferred promoters and response elements which respond to energy/ionic stress in the methods and kits of this invention are the promoters of the FOS and GRP78 genes and the CRE response element.

FOS, which is described above, contains the cAMP response element ("CRE") [W. J. Roesler et al., J. Biol. Chem., 263, pp. 9063-9066 (1988)].

GRP78, which is also described above, contains an energy/ionic stress responsive element that responds to calcium ionophores.

CRE is the cAMP response element. It is an energy/ionic stress-sensitive response element which responds to increased levels of cAMP [J. Roesler et al., J. Biol. Chem., 263, pp. 9063-66 (1988)].

Other energy/ionic stress promoters that may be employed in the kits and methods of this invention are listed in Table 2, below. In the brief description of each of these genes that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets.

Two cytochrome P450 genes -- CYP11B2 which is induced by cAMP; and CYP2E1, which is induced by ethanol -- contain energy/ionic stress responsive elements. 2'-5' AS contains an element which responds to energy/ionic stress induced by ethanol. DBH, which encodes dopamine β -hydroxylase [B. Grima, Nature, 326, pp. 707-11 (1987)] and TH, which encodes tyrosine hydroxylase [A. Lamouroux et al., EMBO J., 6, pp. 3921-37 (1987)] are both induced by membrane depolarization. ODC, which encodes ornithine decarboxylase, is induced by osmotic shock [N. J. Hickok et al., DNA, 6, pp. 179-87 (1987)]. G6PD encodes glucose-6-phosphate dehydrogenase and is induced by ATP depletion. PKC contains an energy/ionic stress-responsive element which is induced by Na/K ATPase depletion. PVALB encodes parvalbumin and is induced by calcium ions (C). Lutum et al. GenBank Accession number X63070]. Stromelysin-1 contains an energy/ionic stress-responsive element which is induced by calcium ionophores.

TABLE 2
Other Mammalian Stress Promoters

Promoter	Redox	DNA	Protein	Energy/ Ionic
UGT	X			
CYP11B2	X			X
Cu.ZnSOD	X			
MnSOD	X	X		
NMO 1	X			
ALDH 2	X			
ADPRT	X			
GP	X		X	
GAS 2,3		X		
EGR-1		X		
MGMT		X		
DNA Pol		X		
beta-pol		X		
DHFR		X		
TK		X		
PCNA		X		
PGHS		X		
LOX		X		
ISG15		X		
DRA		X		
MDR-1		X		
2'-5' AS		X		X
FAOxase	X			
PBE	X			
PPAR	X			
MT 1A/IIIA			X	
TH				X
DBH				X
ODC				X
EH	X	X		
CYP2B2	X			

Table 2 (cont'd)

Promoter	Redox	DNA	Protein	Energy/ Ionic
CYP2E1	X	X		X
CYP3A3	X			
P450b	X			
P450d	X			
TPO1/TPO2		X		
PPa	X	X		
G6PD				X
PKC	X			X
PVALB				X
Stromelysin-1		X		X
GST2	X			
GAPDH	X			
NQO	X			
PCNA		X		
ARE	X			

Because response elements can only be isolated from the promoters which contain them by recombinant DNA methods, the use of such elements in the kits and methods of this invention is limited to embodiments utilizing promoter-heterologous gene constructs.

In order to operatively link a response element to a heterologous gene, it must first be ligated to a minimal promoter. A minimal promoter is one which constitutively causes a basal expression of a gene operatively linked thereto. Preferred minimal promoters are the SV40 minimal promoter, the TK minimal promoter or the β -interferon minimal promoter. These minimal promoters are well known in the art. This minimal promoter/response element construct is then operatively linked to the heterologous gene by well-known recombinant DNA methods.

Many of the above described promoters, or functional equivalents thereof, are present in other eukaryotes, such as nematodes, yeast, insects, reptiles, amphibians and plants.

For example, yeast contain a metallothionein gene, CUP, that responds to protein stress induced by exposure to heavy metals [T. R. Butt et al., *Gene*, 27, pp. 23-33 (1984); T. R. Butt et al., *Proc. Natl. Acad. Sci. USA*, 81, pp. 3332-36 (1984)]. Yeast also contain equivalents of the HSP70 and GRP 78 genes [E. A. Craig, *In Stress Proteins In Biology And Medicine*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp. 301-21 (1990); W. R. Boorstein et al., *J. Biol. Chem.*, 265, pp. 18912-21 (1990); and M. D. Rose et al., *Cell*, 57, pp. 1211-21 (1990)]. Alcohol dehydrogenases, a family of yeast genes that are induced by alcohol, an energy/ionic stress have also been sequenced [T. Young et al., *Basic Life Sci.*, 19, pp. 335-361 (1982)].

Also, a large number of DNA stress genes have been identified and sequenced in yeast. These include MAG, the methyladenine DNA glycosylase, and MGT1, which respond to DNA alkylation damage [W. Xiao et al., *Mol. Cell Biol.*, 13, pp. 7213-21 (1993)]; RAD51, RAD54, RAD6, RAD23, RAD2, RAD18 and RAD7, all of which respond to DNA strand breaks [G. Basile et al., *Mol. Cell. Biol.*, 12, pp. 3235-46 (1992); G. M. Cole et al., *Mol. Cell Biol.*, 9, pp. 3314-3326 (1989); K. Madura et al., *Nucleic Acids Res.*, 18, pp. 771-78 (1990); *Nucleic Acids Res.*, 18, pp. 4737-42 (1990); K. Madura et al., *J. Bacteriol.*, 166, pp. 914-23 (1990); J. S. Jones et al., *Nucleic Acids Res.*, 19, pp. 893-98 (1991); J. S. Jones et al., *Nucleic Acids Res.*, 18, pp. 3281-85 (1990)]; PHR1 which is induced by DNA damaging agents [J. B. Sebastian et al., *Mol. Cell Biol.*, 10, pp. 4630-37 (1990)]; RNR2 and RNR3, the yeast ribonucleotide reductases, which are induced by DNA damage [S. J. Elledge et al., *Mol. Cell Biol.*, 9, pp. 5373-86 (1989); S. J. Elledge et al., *Gene Dev.*, 4, pp. 740-51 (1990); Z. Zhou et al., *Genetics*, 131, pp. 851-66 (1992)]; CDC9, the yeast DNA ligase [T. A. Peterson et al., *Mol. Cell Biol.*, 5, pp. 226-35 (1985)]; UBI4, another gene that responds to DNA damage [J. M. Treger et al., *Mol. Cell Biol.*, 8, pp. 1132-36 (1988)]; and DDR48, a gene which responds to mutagens [J. M. Treger et al., *Mol. Cell Biol.*, 10, pp. 3174-84 (1990)]. In addition, several other DNA stress genes have also been identified in yeast [G. W. Robinson et al., *Proc. Natl. Acad. Sci. USA*, 83, pp. 1842-46 (1986); S. W. Ruby et al., *Mol. Cell Biol.*, 5, pp. 75-84 (1985); E. C. Friedberg, *Microbiol. Rev.*, 52, pp. 70-102 (1988); T. McClanahan et al., *Mol. Cell Biol.*, 4, pp. 2356-2363 (1984)].

(1984)].

The appropriate combination of any or all of these promoters, as well as other known yeast stress promoters, may be utilized in the methods and kits of this invention. It will be understood that if yeast stress promoters are employed, yeast hosts are preferred and should be grown under conditions appropriate for such a host. Such conditions are well known in the art.

The most preferred kits and methods which utilize oligonucleotides to detect toxicity comprise the following stress promoters: ALDH1, CYP1A1, FOS, GADD153, HMO, HSP70, JUN and MTIIA. The most preferred kits and methods which utilize reporter gene expression to detect toxicity comprise the following stress promoters and response elements: CYP1A1, GST Ya, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE and p53RE.

According to another embodiment of this invention, the diagnostic kits and methods additionally employ at least one cell surface receptor-mediated stress promoter. Such kits and methods are particularly useful for determining and characterizing the toxicity of a compound on external organs, such as skin, the eye or mucous membranes. The use of cell surface receptor-mediated stress promoters allows for the detection of compounds which can cause local irritation or inflammation of such external organs.

Irritants and inflammatory agents may cause sub-lethal cell injury that cannot be detected histologically. Such toxins would not be toxic to an animal as a whole in a classic sense and thus may escape detection by methods such as live animal testing. The use of cell surface receptor-mediated stress promoters in the kits and methods of this invention allow for the detection and characterization of such local irritants or inflammatory agents, as well as the ability to distinguish between the two on a subcellular level -- something that whole animal testing cannot achieve.

The preferred cell surface receptor-mediated stress promoters for use in such kits are selected from the promoters of the IL-1 alpha, G-CSF, GM-CSF, TNF-alpha, IL-3, IL-6, IL-8, ICAM-1 and stromelysin-1 genes.

The Interleukin (IL)-1 alpha gene encodes a cytokine that is induced by mitogens, lipopolysaccharide (LPS), PMA, silica, other cytokines, and UVB irradiation [T. A. Luger et al., *J. Invest. Dermatol.*, 95, pp. 100S-104S (1990)]. The sequence of that gene is described in Y. Furutani et al., *Nucleic Acids Res.*, 14, pp. 3167-79 (1986).

The granulocyte colony stimulating factor (G-CSF) gene produces a protein that is induced by endotoxin, interferons, and PMA [T. A. Luger et al., *J. Invest. Dermatol.*, 95, pp. 100S-104S (1990)]. The sequence of this gene is described in S. Nagata et al., *EMBO J.*, 5, pp. 575-581 (1986).

The granulocyte macrophage colony stimulating factor (GM-CSF) gene encodes a protein that is produced in response to the same stimuli as G-CSF [T. A. Luger et al., *supra*]. The sequence of this gene is described in S. Miyatake et al., *EMBO J.*, 4, pp. 2561-2568. (1985).

The tumor necrosis factor (TNF) alpha gene encodes a protein that is induced by IL-1 alpha and IFN gamma [B. J. Nickoloff et al., *J. Invest. Dermatol.*, 94, pp. 151S-157S (1990)]. The sequence of this gene is described in D. Semon et al., *Nucleic Acids Res.*, 15, pp. 9083-9084 (1987).

The IL-3 gene encodes a product of the same name and is induced by interferon (IFN) gamma, PMA, and UVB irradiation [T. A. Luger et al., *supra*]. The sequence of that gene is described in D. R. Cohen et al., *Nucl. Acids Res.*, 14, pp. 3641-58 (1986).

The IL-6 gene produces a protein that is expressed in response to other cytokines, bacterial toxins, viruses, tumor promoters and sodium lauryl sulphate [T. Hunziker et al., *Brit. J. Dermatol.*, 127, pp. 254-57 (1992) and T. A. Luger et al., *J. Invest. Dermatol.*, 95, 100S-104S (1990)]. The sequence of this gene is described in K. Yasukawa et al., *EMBO J.*, 6, pp. 2939-45 (1987).

The IL-8 gene is induced by the cytokines IL-1 alpha, tumor necrosis factor (TNF-alpha), and IFN-gamma, as well as by LPS, and tumor promoters [I. C. Oliveira et al., *Proc. Natl. Acad. Sci. USA*, 89, pp. 9049-53 (1992)]. The sequence of that gene is described in N. Mukaida et al., *J. Immunol.*, 143, pp. 1366-71 (1989).

The intracellular adhesion molecule (ICAM)-1 gene encodes a protein that is induced by cytokines, LPS, hydrocortisone, and PMA [S. W. Caughman et al., *J. Invest. Dermatol.*, 98, pp. 61S-65S (1992)]. The sequence of this gene is described in B. G. Stade et al., *Immunobiology*, 181, pp. 851-56 (1990).

The stromelysin-1 gene contains a cell surfaced receptor-mediated stress element that is induced by epidermal growth factor.

Other cell surface receptor-mediated stress promoters that may be utilized in the kits and methods of this invention include the promoters of IL-1 beta, TGF-alpha, IL-10 and M-CSF genes, as well as the promoters of the genes that encode the cell surface receptor that regulates the expression of any of the above genes. In the brief description of each of these genes that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets.

The IL-1 beta gene is induced by the same agents as the IL-1 alpha gene [J. Huang et al., *J. Immunol.*, 140, pp. 3838-43 (1988)]. The transforming growth factor (TGF) alpha gene encodes a protein that is induced by itself as well as by IFN-gamma [F. Iris et al., *Nature Genetics*, 3, pp. 137-45 (1993)]. IL-10 is induced by contact allergens such as trinitrochlorobenzene (TNCB) and haptens [J. M. Kim et al., *J. Immunol.*, 148, pp. 3618-23 (1992)]. The other cell surface receptor-mediated stress genes have also been described in the art.

The diagnostic kits and methods of this invention rely on the induction of specific stress promoters or stress response elements and the transcription and/or translation of a gene operatively linked thereto.

For embodiments of the invention that employ a heterologous gene operatively linked to a mammalian stress promoter or stress responsive element, the choice of gene is essentially limitless. The only parameters that are required are (1) that a DNA sequence encoding the assayable product has been characterized; and (2) that the product of the gene can be detected. Sufficient characterization includes knowledge of the entire coding sequence, availability of a genomic clone or knowledge of a sufficient number of restriction sites within the genomic DNA sequence to allow the gene to be manipulated so as to create an operative linkage to the stress promoter.

Promoters of most mammalian stress genes are inducible by more than one type of stress. This is because such promoters contain within their sequence a number of stress response elements, each of which is responsive to a different type of stress. In embodiments that utilize such multiple stress promoters it is preferable that another promoter which responds to only one of the multiple stresses also be employed. This is true whether native promoter-gene systems or recombinant promoter-assayable gene fusions are used. For example, the HMO promoter and the JUN promoter are induced by both peroxides and by UVA rays. Thus, these promoters respond to both redox stress and DNA stress. An NMO1 promoter, which responds solely to oxidative stress, may be used together with an HMO or JUN promoter. This combination of promoters allows one to determine whether induction of the multiple stress promoter was due to redox stress or UVA light. In this manner, the nature of the stress caused by a compound can be more accurately determined.

According to another embodiment of this invention, individual response elements of a promoter may be isolated and then operatively linked to a mammalian minimal promoter and to a gene which encodes a detectable product. Thus, expression of the detectable product in the presence of a compound is correlated with only one particular type of stress.

In embodiments which employ a gene encoding a detectable product, the assayable product is preferably β -galactosidase (encoded by the lacZ gene), chloramphenicol acetyl transferase (encoded by the CAT gene), galactose kinase (encoded by the galK gene), β -glucosidase (encoded by the gus gene), glutathione transferase, human growth hormone (encoded by the hGH gene) or firefly luciferase (encoded by the lux gene). Most preferably, the CAT gene is employed.

The stress promoter-assayable product fusions harbored by the hosts employed in certain of the diagnostic kits and methods of this invention may be made using standard recombinant DNA techniques that are well known in the art. The choice of techniques depends upon what is known about the particular stress promoter to be used in the strain.

If a genomic fragment containing a stress promoter and its gene have been isolated or cloned into a vector, the promoter is removed by appropriate restriction enzyme digests. The promoter fragment is then isolated and operably linked to a gene encoding an assayable product in a plasmid. The vector should also contain a marker, such as Neo, for identifying stable transfectants. Screening for a functional fusion is achieved by exposing transfectants to a stress which is known to induce the specific stress promoter and assaying for the detectable gene product.

If the nucleotide sequence of the stress promoter and its gene is known, polymerase chain reaction technology may be employed to produce assayable protein fusions. Specifically, one synthesizes primers which are complementary to the 5' and 3' ends of the stress promoter portion of the gene, hybridizes those primers to denatured, total mammalian DNA under appropriate conditions and performs PCR. In this manner, clonable quantities of any sequenced stress promoter may be obtained. Once the stress promoter DNA has been obtained, it is operatively linked to a DNA encoding an assayable protein in an appropriate vector, as described above. Such methods are well-known in the art.

Constructing operable fusions of stress promoter response elements to a gene encoding a detectable product is also carried out by standard recombinant DNA techniques. Because response elements are small, DNA encoding them may be produced using an oligonucleotide synthesizer. Oligonucleotides corresponding to both strands of the response element are synthesized, annealed together and cloned into a plasmid containing a reporter gene under control of a minimal promoter. Alternatively, the double stranded oligonucleotides can be allowed to multimerize via self ligation prior to insertion into a vector. The multiple copies of the response element allow for higher expression of the detectable product upon stress induction.

Embodiments of the present invention that employ native stress genes as the genes encoding an assayable product require no genetic manipulation prior to assaying toxicity.

The choice of cell line to use in the kits and methods of this invention is dependent upon the assay to be used to determine toxicity. For those embodiments which utilize stress promoter-assayable product gene fusions, the cells must be able to produce the expression product in assayable form. Moreover, those cells should not constitutively produce the assayable product from another copy of the gene in their genome.

For embodiments which utilize the cell's native stress genes, the choice of cells is based upon the ability of those genes to be induced by stress. Preferred cells for embodiments that do not employ cell surface receptor-mediated stress promoters are HeLa, HepG2 and WIL-2. For those kits and methods that do employ cell surface receptor-mediated stress promoters, the preferred cell line is one derived from the organ of concern. For example, if the stress

kits and methods are intended to identify compounds which affect the skin, a skin fibroblast or keratinocyte cell line, such as SCC12 or its derivatives, such as C6C1, is preferred. For kits and methods seeking to identify toxins to the eye, a corneal cell line is most preferred.

When utilizing stress promoter-assayable product fusions, it is preferable that each host employed in the kits and methods of this invention harbors only one such fusion. In this manner, if a compound induces expression of the assayable gene product in any particular host cell, the specific type of stress caused by the compound can unambiguously be identified.

It is known that some compounds are not toxic to mammals in their native form, but become toxic after being processed by the liver. Therefore, according to another embodiment of this invention, the compound to be tested in the methods and kits of this invention is pre-treated with an S9 liver extract. Methods for preparing an S9 liver extract ("S9") are described by S. Vennitt et al., In Mutagenicity Testing - A Practical Approach, S. Vennitt et al., eds., IRL Press, Oxford, England, pp. 52-57 (1984). S9 is generally a crude homogenate of rat liver with insoluble particles removed by low speed centrifugation, but may also be prepared from human or other mammalian liver. S9 is incubated with the test compound in a potassium buffer containing NAD(P)H to mimic stage I and stage II biotransformation of compounds normally performed by the mammalian liver prior to performing the toxicity assay. If, however, primary mammalian liver cells are utilized in the kits and methods of this invention, S9 pre-treatment is unnecessary. The cells will be capable of performing stage I and II biotransformation of compounds under assay growth conditions.

Alternatively, the cells utilized in the kits and methods of this invention are co-cultured with cells capable of performing stage I and II biotransformation, preferably, a primary liver cell line. The biotransformation of the compound being assayed is, in this instance, performed by those other cells, rather than enzymatic fractions derived from liver cells.

Prior to carrying out an assay on a compound of unknown toxicity using the methods and kits of this invention, standard curves should be generated utilizing at least one and preferably at least three compounds that are known to induce each specific stress promoter or response element that will be used to screen the unknown compound.

Each known chemical should more preferably be tested against all of the promoters, not just the promoter that it is known to induce. And each chemical should be assayed over a sufficiently wide range of concentrations to provide a useful standard curve, preferably 1 picomolar to 1 millimolar as well as at several time points.

Once the standard curves have been generated, a computer data base containing those curves is generated. This database is then used to compare stress promoter-induction profiles of the compounds to be tested with those of the known toxins used to generate the standard curve. Thus, the results for any untested compound are expressed in terms of relative toxicity compared to known inducers of stress promoters.

Each of the characterization and toxicity determination methods of this invention comprise the first step of culturing the cells both prior to and following exposure to a potential toxic compound. Culture conditions will vary depending upon the cell type utilized. Most preferably, immortalized human liver cells (HepG2) are used. Growth of these cells is performed under standard tissue culture conditions -- minimal essential medium at 37°C, 5% CO₂. The cells are routinely grown in 165 cm² flasks until they reach a density of about 5 x 10⁶ cells/ml.

Following this initial growth, the cells are subcultured and exposed to the compound to be tested. A typical assay employs approximately 2.75 x 10⁵ cells/ml. For initial tests on a compound, a series of 10-fold dilutions of the compound should be used. Another series of dilutions of the compound which have been pre-incubated with S9 fraction should also be prepared and added to a second portion of each culture. A third portion of each culture, which serves as a control, is not exposed to the compound, but otherwise treated in the same manner as described below.

All of the cultures are then allowed to incubate at normal growth temperature for a period of time ranging from 5 minutes to 48 hours. More preferably, exposure to the toxic or test compound is for about 2 to 32 hours. Following exposure to the test compound, the level of assayable product or stress gene mRNAs are measured.

If the embodiment measuring assayable product is employed, quantification may be carried out in a number of ways that are well known in the art. For example, a colorimetric substrate may be utilized if the expression product is an enzyme. Appropriate colorimetric substrates for specific enzymes are well-known in the art. Alternatively, an assay which employs specific antibodies, such as an RIA or ELISA, can be used to detect the expression product.

Depending upon the nature of the assay used, the buffer conditions of the lysed culture or supernatant may need to be adjusted. Accordingly, suitable buffer may be added to the lysed culture or supernatant so that optimal conditions for the particular assay are obtained. For example, if the assayable product is to be detected by an RIA or ELISA assay, the buffer conditions must be adjusted to a neutral pH to allow for maximal antibody-antigen complex formation and to minimize non-specific antibody binding. Such conditions are well known in the art and are exemplified by a final buffer condition of 50 mM phosphate buffer, 150 mM NaCl, pH 7.0. If the assayable product is an enzyme and detection is to be achieved by a colorimetric substrate assay, buffer conditions must be optimized for maximal enzymatic activity and minimal non-catalytic cleavage of the substrate. These conditions are conventional and vary depending on the enzyme to be assayed.

In the most preferred embodiment of this aspect of the invention, the detectable product is chloramphenicol acetyl transferase (CAT). Assays for this enzyme are well-known in the art and are described in J. Sambrook et al., "Molecular

Cloning - A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press, pp. 16.60-16.65 (1989). That reference also describes assays for β -galactosidase, another assayable product useful in the methods and kits of this invention (pp. 16.66-16.67).

In embodiments that utilize transcription level to determine stress gene induction, the level of mRNA transcribed from genes operatively linked to the stress promoters utilized in the kits and methods of this invention must be measured ("stress gene mRNA"). This requires that total RNA or mRNA be isolated from exposed cells. This may be achieved by any of the numerous and well-known methodologies. Commercially available mRNA or total RNA isolation kits may also be utilized, such as is available from Strategene [La Jolla, CA]. Preferably the cells are lysed with guanidinium isothiocyanate (GTC). The lysate is then acidified with sodium acetate buffer (pH 5.2) and the contaminants extracted with phenol. The RNA is then twice precipitated with ethanol, dried and redissolved in water.

Once the RNA has been isolated, the level of stress gene mRNA can be measured in a number of ways, either directly or indirectly. In the direct method, oligonucleotides that are complementary to stress gene mRNA are used. In this method, the mRNA isolated from the cells is applied to nitrocellulose paper or nylon membrane filter in a slot blot apparatus. After diluting the RNA in the apparatus with appropriate salt solution (preferably two volume of 20X SSC) and washing the slots, the nitrocellulose paper or filter is either baked at 80°C for 2 hours in a vacuum oven or UV crosslinked to fix the RNA. The RNA fixed to the nitrocellulose is then hybridized to labeled oligonucleotide probes which are complementary to stress gene mRNAs under appropriate buffer and temperature conditions.

An indirect method utilizes oligonucleotides that are homologous to stress gene mRNAs for detection. This method measures transcription by using the stress gene mRNAs as templates for making labelled single stranded cDNA using reverse transcription. These cDNAs are then detected and quantitated by hybridizing to complementary oligonucleotides (or denatured doublestranded cDNAs) that are bound to a solid support. Preferably, the solid support is a negatively charged membrane and the oligonucleotides are modified by the addition of a positively charged amidite or amino group on the 3' end prior to binding to the membrane. This 3' modification allows the oligonucleotide to bind to the membrane only via its 3' end, allowing for more efficient hybridization than other methods of binding DNA to a solid support.

In either method, a control representing a constitutively expressed "housekeeping gene", such as β -globin, β -tubulin, β -actin or γ -actin, which is not induced by the specific experimental sample, is also used. This provides a control for proper growth and functioning of the cells, as well as the background standard upon which to calculate the amount of specific induction. Following hybridization, the amount of hybridization is quantified. Quantification is achieved by a method that is consistent with the label on the oligonucleotide or cDNA. If a radioisotope is used as a label, exposure of the membrane to X-ray film followed by densitometry tracing or liquid scintillation counting would be the preferred methods of quantification. If a fluorescent label is used, a fluorometer is used for quantification. In this manner the level of various stress gene inductions can be measured. If a biotinylated label is used, quantification is achieved by using streptavidin conjugated to an enzyme that can yield a measurable colorimetric product.

It is known that while individual compounds may not be toxic, combinations of non-toxic compounds may in fact be toxic. Therefore, it should be understood that the kits and methods of this invention can also be utilized to determine the potential toxicity of combinations of known and unknown compounds (eg. drug interactions) in an identical manner to that described above.

This invention also provides stress-specific diagnostic kits and methods. For example, the invention provides redox stress kits and methods; DNA stress kits and methods; protein stress kits and methods; energy/ionic stress kits and methods; and receptor-mediated stress kits and methods. The choice of promoters to use in these stress-specific kits may be made from any of the appropriate promoters described or listed in Tables 1 and 2, above. Preferably these kits employ at least 3, and more preferably at least 8, promoters which respond to different subsets of stresses within the larger group. Most preferably, these specific kits and methods employ at least 12 promoters in those tables which respond to the appropriate stress. These kits and methods allow a more precise and specific analysis of the stresses caused by a compound.

According to another embodiment, the invention provides a method of identifying an antitoxin to a compound determined to be toxic by the methods of this invention. As described above, once a stress promoter induction profile is generated for an unknown compound, that profile is compared to profiles of known compounds in a database. A potential antitoxin to the unknown compound is a known antidote to a compound having a similar stress promoter induction profile.

In order to test the efficacy of such an antitoxin, the stress promoter assay is repeated using only those hosts containing stress promoters which were induced by the unknown compound. Each of those hosts is pre-incubated with varying concentrations of the proposed antitoxin prior to the addition of an inducing concentration of unknown compound. If pre-incubation with the proposed antitoxin decreases or obliterates the effect of the unknown compound, such an antitoxin will likely be effective.

Finally, this invention provides a method of improving active drug design. According to this embodiment, a new drug is first tested with any of the above-described kits and methods and its toxicity is determined. The information

provided by such methods and kits indicates the cellular mechanism of the drug's toxicity. The portion of the drug that is likely to cause the particular cellular damage indicated may then be appropriately modified or eliminated depending upon the role that portion plays in the drug's pharmaceutical activity. The resulting modified drug is then retested with the kits and methods of this invention to determine if its toxicity has been sufficiently reduced or eliminated. Drugs improved and modified by this method are also within the scope of this invention.

In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

Certain of the basic molecular biology techniques described below are not set forth in detail. Such techniques are well known in the art and are described in the disclosure of Molecular Cloning - A Laboratory Manual Second Edition, J. Sambrook et al., eds., Cold Spring Harbor Laboratory Press, New York (1989).

EXAMPLE 1

Design And Synthesis Of Stress Gene-Specific Oligonucleotide Probes

The nucleotide sequence of each of the stress genes described herein is known. Accordingly, design of specific oligonucleotides is simply a matter of choosing what portion of the gene to model upon. The computer program OLIGO allows one to enter the nucleotide sequence of the gene of interest and analyze the sequence to determine position, length, and composition of oligonucleotides which will hybridize to the sequence of interest at salt concentrations and temperatures selected by the user. Using this program, I have designed the following stress gene-specific complementary oligonucleotides for use in the kits and methods of this invention:

GADD 153 gene: [SEQ ID NO. 1] 5'-AAAAAAACCCAGTCCAACTA
CAGACATGGCAGCTGAGTCCCTGCCATTCACCTTGGAGACGGTGTGTTTTTT-3' ;

XHF1 gene: [SEQ ID NO. 2] 5'-AAAAAAGGCCAGTATGCACAGC
TTTCCTCCACTGCTGCTGCTGCTGTTCTGGGGTGTGGTGTCTTTTTTT-3' ;

JUN gene: [SEQ ID NO. 3] 5'-AAAAAACCCCAAGATCCT
GAAACAGAGCATGACCCTGAACCTGGCCGACCCAGTTTTTTT-3' ;

MnSOD gene: [SEQ ID NO. 4] 5'-AAAAACAACCTGAAC
GTCAACGAGGAGAAGTACCAGGAGGCGTTGGCCAAGGGAGATTTTTTT-3' ;

HMO gene : [SEQ ID NO. 5] 5'-AAAAATAGAGCGTCCGCA
ACCCGACAGCATGCCCCAGGATTTGTCAGAGGCCCTTTTTTT-3' ;

GST Ya gene: [SEQ ID NO. 6] 5'-AAAAAAGGAGTTGGGAGCTG
AGTGGAGAAGAAGCCACGACTCTCGCTAGGTCAGTACTCTTTTTTT-3' ;

HSP70 gene: [SEQ ID NO. 7] 5'-AAAAAAGCCGCGGCAGTCG
GCATCGACCTGGGCACCACTACTCCTGCGTGGGGGTGTTCCAATTTTTTT-3' ;

MDR-1 gene: [SEQ ID NO. 8] 5'-AAAAAAATTACAGCAAGCC
TGGAACCTATAGCCCCTTTAACTTGAGCAGCATCATTTTTTTT-3'

5

CYP 1A1 gene: [SEQ ID NO. 9] 5'-AAAAAACATTCAGGGAAGG
GTTGGGTAGGTAGCGAAGAATAGGGATGAAGTCAGCTTTTTTTT-3'

10

FOS gene: [SEQ ID NO. 10] 5'-AAAAAATGCTGGAGAAGG
AGTCTGCGGGTGAGTGGTAGTAAGAGAGGCTATCCCCTTTTTT-3'

15

NMO1 gene: [SEQ ID NO. 11] 5'-AAAAAAGGAATCTCATTTT
CTAGCTTTGATCTGGTTGTCAGTTGGGATGGACTTGCTTTTTTT-3'

20

ALDH2 gene: [SEQ ID NO. 12] 5'-AAAAACCTCTTGCTTCCC
CGTGTTGATGTAGCCGAGGATCTTCTTAACTGAGTTTTTTTT-3'

25

DRA gene: [SEQ ID NO. 13] 5'-AAAAACAGTGGTCAATGTCA
CGTGGCTTCGAAATGGAAACCTGTCACCACAGGATTTTTTT-3'

30

MGMT gene: [SEQ ID NO. 14] 5'-AAAAAAGGATTGTGAAATG
AAACGCACCACACTGGACAGCCCGTTGGGGAAGCTGGAGCTGTCTTTTTT-3'

35

2'-5' AS gene: [SEQ ID NO. 15] 5'-AAAAAATTCTTACAATTTT
GGTACCAGTGCTTGACTAGGCGGATGAGGCTCTTGAGTTTTTT-3'

40

DHFR gene: [SEQ ID NO. 16] 5'-AAAAAAGTCTTGCAATGATCCTT
GTCACAAATAGTTTAAGATGGCCTGGGTGATTCTTTTTT-3'

45

Cu.ZnSOD gene: [SEQ ID NO. 17] 5'-AAAAAACCAGCACCCCGTCT
CCGCGACTACTTTATAGGCCAGACCTTTTTT-3'

50

ALDHA1 gene: [SEQ ID NO. 18] 5'-AAAAAAACCGTACTCTCC
CAGTTCTCTTCCATTTCCAGACATCTTGAATCCACCATTTTTT-3'

55

TK gene: [SEQ ID NO. 19] 5'-AAAAAAGAGTGTCTTTGGC
ATACTTGATCACCAGGCACTTGTACTGAGCAATCTGGTTTTTT-3'

PVALB gene: [SEQ ID NO. 20] 5'-AAAAAAAACACCTTCTTC
ACATCATCCGCACTCTTTTCTTCAGGCCGACCATTTTTTTTTT-3'

TH gene: [SEQ ID NO. 21] 5'-AAAAAGAAGCTCTCAGACAC
GAAGTAGACTGACTGGTACGTCTGGTCTGGTAGGTTTTTT-3'

EH gene: [SEQ ID NO. 22] 5'-AAAAATCTAGAATATAGG
CAGCCAGACCCACAGGAGAGTCATTCAGAGCAGAGCCTTTTTT-3'

TOP1 gene: [SEQ ID NO. 23] 5'-AAAAAAGATAGCGCTCTTCTTC
CCACCATTCCACTTCTGTTCCTCTTCTTCTTTTCTTTTTT-3'

TOP2 gene: [SEQ ID NO. 24] 5'-AAAAAGCCTCTGCCAGTTTTTCTT
CAGTCATCTTCACAACAAATTTACAGTGGTTTTTTT-3'

MT 1A gene: [SEQ ID NO. 25] 5'-AAAAATCTCTTCCTTGCAG
GTGGCTCCTGCACCTGCACTGGCTCCTGCAAATGCAAAGAGTTTTTT-3'

The synthesis of the above oligonucleotides was carried out as follows. The specific oligonucleotide was synthesized using an automated oligonucleotide synthesizer [Model 392, Applied Biosystems, Foster City, CA].

I have also designed the following oligonucleotides which are homologous to the indicated stress gene mRNAs, based on the reported nucleotide sequence of the various genes or cDNAs thereof:

ALDH1 gene: [SEQ ID NO. 26] 5'-AATTGCTATGGCGTGGTAAGTG
CCCAGTGCCCCTTTGGTGGATTCAAGAT-3'

CYP1A1 gene: [SEQ ID NO. 27] 5'-ATCTGAGTTCCTACCTGAACGGT
TTCTCACCCCTGATGGTGCTATCGACA-3'

FOS gene: [SEQ ID NO. 28] 5'-GTACTCCCAGCTGCACTGCT
TACACGTCTTCCTTCGTCTTCACCT-3'

GADD153 gene: [SEQ ID NO. 29] 5'-AGGAGAATGAAAGGAAAGTGGC
ACAGCTAGCTGAAGAGAATGAACGGCTC-3'

GADD45 gene: [SEQ ID NO. 30] 5'-AGTCGCTACATGGATCAATGGGT
TCCAGTGATTAATCTCCCTGAACGGTG-3'

GAPDH gene: [SEQ ID NO. 31] 5'-GTGGTGGACCTGACCTGCCGTCT
AGAAAAACCTGCCAAATATGATGACAT-3'

5

GST2 gene: [SEQ ID NO. 32] 5'-CAGCCCAAGGAAGCCTCCCATGG
ATGAGAAATCTTTAGAAGAAGCAAGGA-3'

10

HMO gene: [SEQ ID NO. 33] 5'-CTTACACTCAGCTTTCTGGTGGCG
ACAGTTGCTGTAGGGCTTTA-3'

15

HSP70 gene: [SEQ ID NO. 34] 5'-AGAAGGACGAGTTTGAGCACAAG
AGGAAGGAGCTGGAGCAGGTGT-3'

20

JUN gene: [SEQ ID NO. 35] 5'-GCTCAGGGAACAGGTGGCACAGC
TTAAACAGAAAGTCATGAACCACGTTA-3'

25

MDR1 gene: [SEQ ID NO. 36] 5'-GAAAGGCATCTATTTTCAATGGT
CAGTGTCCAGGCTGGAACAAAGCGCC-3'

30

MT1A gene: [SEQ ID NO. 37] 5'-GCACTGGCTCCTGCAAATGCAAA
GAGTGCAAATGCAACTCCTGCAAG-3'

35

MT1IA gene: [SEQ ID NO. 38] 5'-CCCAGGGCTGCATCTGCAAAG
GGGCGTCGGACAAG-3'

40

NMO gene: [SEQ ID NO. 39] 5'-ACCACTGTATTTTGCTCCAAGCAGC
CTCTTTGACCTAAACTTCCAGGCAG-3'

45

PCNA gene: [SEQ ID NO. 40] 5'-ACAAAAGCCACTCCACTCTCTTCA
ACGGTGACACTCAGTATGTCTGCAGA-3'

50

NQO gene: [SEQ ID NO. 41] 5'-TTGCTCTCGACAGTATCCACAAT
AGCTGACGGCTGGGTGTTTCAGTTTGA-3'

I also designed the following control oligonucleotides which are homologous to housekeeping gene transcripts:

55

ACTG (gamma-actin) gene: [SEQ ID NO. 42] 5'-ACCTTCCAGCA
GATGTGGATTAGCAAGCAGGAGTACGACGAGTCG-3'

BTUB (beta-tubulin) gene: [SEQ ID NO. 43] 5'-TTGAGTGG
ATCCCCAACAAATGTGAAAACGGCTGTCTGTGACATCCACCT-3'.

These oligonucleotides were each modified at their 3' end by the addition of an amino group so that they could bind to a negatively charged membrane only via their 3' end. Such oligonucleotides were synthesized to order by Operon Technologies, Inc., Alameda, CA.

Complementary and homologous oligonucleotide probes for any of the other stress gene mRNAs that may be employed in this invention may be similarly designed using the software described above.

EXAMPLE 2

Toxicity Assay Of An Unknown Compound Using Radiolabelled Oligonucleotide Probes

I. Direct Quantification of Stress Gene mRNA by Hybridization to Oligonucleotide Probes

It is desirable to know if unknown compound "X" is toxic and, if it is, what type of damage it causes to mammalian cells.

HepG2 cells are grown in 165 cm² flasks containing minimal essential medium (Gibco/BRL, Gaithersburg, MD) until they reach a density of approximately 8×10^6 cells/ml. The cells are then subcultured by diluting them to 5×10^6 cells/ml and plated at 10 ml/plate. Several plates of each subculture are exposed to a different concentration of compound X (1 pM to 1 mM in a series of 10-fold dilutions). Messenger RNA is isolated from subcultures after 2, 4, 8, 16 and 32 hours, as described below.

The medium is removed from the cell monolayers by aspiration and the cells are washed twice with cold phosphate buffered saline. I then add 2 ml of cold phosphate buffered saline to the monolayer and use a rubber policeman to scrape the lysate into 15 ml disposable polypropylene tubes. Total RNA was isolated using the RNeasy B reagent (Biotech Laboratories, Houston, TX), following manufacturer's directions. The RNA pellet is dried and redissolved in 10 μ l water. A normal yield of RNA is about 100-200 μ g/plate.

RNA from each two replicate plates is then applied to 20 different slots in a slot blot apparatus as follows. The slot blot apparatus is cleaned prior to use in 0.1 N NaOH. A piece of nitrocellulose paper or nylon membrane filter (10.45 μ m pore size) is briefly wetted in water and then soaked in 20X SSC for 1 hour at room temperature. The filter is then placed in the apparatus. The RNA sample from each plate is mixed with 20 μ l of 100% formamide, 7 μ l of 37% formaldehyde and 2 μ l of 20X SSC, incubated at 68°C for 15 minutes and then chilled on ice.

Twenty μ g of RNA is applied to each slot in the apparatus together with two volumes of 20X SSC. After the solution drains through the filter, the slots are rinsed twice with 1 ml of 10 X SSC. The filter is then dried and baked at 80°C for 2 hours in a vacuum oven. The filter is then cut into strips so that samples exposed to different concentrations of X for varying periods of time can be hybridized to individual stress gene-specific probes. One strip is used for each separate probe.

Hybridization of the strips to individual oligonucleotide probes are carried out under well known conditions for RNA-DNA hybridization. The temperature and salt concentration for hybridizing various probes to the RNA will depend upon the nature of the oligonucleotide. These conditions can be calculated using well known formulae. Probes to the following genes are used:

redox stress only: CYP1A1, NMO1, ALDH2;
DNA stress only: XHF, DRA, GADD153 and MDR-1;
protein stress only: HSP70, MT 1A;
redox and DNA stress: GST Ya, HMO and MnSOD;
redox, DNA and protein stress: JUN;
DNA, protein and energy/ionic stress: FOS.

Following hybridization, the strips are washed, dried and mRNA levels are quantified in one of two ways. In one method, the strips are exposed to X-ray film and hybridization is quantified by densitometry. Alternatively the strips are put into individual slots and subjected to scintillation counting. Actually, both methods can be carried out if the former

is performed first.

II. Indirect Quantification of Stress Gene mRNA by Hybridization of cDNA to Oligonucleotide Probes

A. Cross-Linking of Oligonucleotides To Negatively Charged Membrane

We separately cross-linked oligonucleotides homologous to the mRNAs of the following stress and housekeeping genes to Biodyne C membranes (Pall Corporation, East Hills, New York) essentially using the method described in Y. Zhand et al., *Nucleic Acids Res.*, 19, pp. 3929-33 (1991):

redox stress only: CYP1A1, ALDH1;
DNA stress only: GADD153;
protein stress only: HSP70;
redox and protein stress: MTIA;
redox and DNA stress: HMO
redox, DNA and protein stress: JUN;
DNA, protein and energy/ionic stress: FOS;
control: γ -actin.

The Biodyne C membrane was first rinsed briefly with 0.1 N HCl. We then treated the membrane for 15 minutes with freshly prepared 20% (w/v) EDC (1-ethyl-3-(3-dimethylaminopropylcarbodiimide)). The membrane was then rinsed with H₂O and placed on a 96-well Dot-Blot apparatus. We then applied the amino-modified oligonucleotides in 0.5M NaHCO₃ (pH 8.4) to the membrane in individual wells using a vacuum for 15 min. The total volume per well should not exceed 3 μ l. Each individual oligonucleotides was applied in four adjacent wells.

After applying the oligonucleotides, we rinsed the membrane with 1 x TBS/0.1% TweenTM-20 and then quenched any remaining active groups on the membrane by treating with 0.1N NaOH for 10 min. We then rinsed the membrane with dH₂O, air dried, and stored the dry membrane in a sealed plastic bag.

B. Treatment of Cells and Isolation of RNA

HepG2 cells are grown in minimal essential medium in 100 mm cell culture dishes to no greater than 80% confluency. The cultures are then exposed to various concentrations of compound X and are incubated at 37°C for the desired length of time. After aspirating off the media, the cells are washed three times with 10 ml of a room temperature phosphate buffered saline solution. 5 ml of the phosphate buffered saline solution is then added to the cell culture dish and the cells are scraped from the dish with a rubber policeman and placed in a 15 ml centrifuge tube. Cells are the counted with a hemacytometer and pelleted in a centrifuge. The phosphate buffered saline is poured off.

If total RNA isolation is desired, we use RNAzol B (Biotecx Laboratories, Inc., Houston, TX), following manufacturer's directions. If only mRNA is desired, the Messenger RNA Isolation Kit (Stratagene Inc., La Jolla, CA) is used, following the manufacturer's directions.

3. Reverse Transcription and Optional PCR of Stress-Specific cDNAs

Total RNA (50 μ g) or mRNA (2 μ g) isolated by the procedures described above is then reverse transcribed using SUPERSCRIPTM II (reverse transcriptase) (Gibco/BRL, Gaithersburg, MD) and the following protocol.

The RNA is added to a microcentrifuge tube with DEPC H₂O and oligo-dT primer. The amount of DEPC H₂O added to the reaction mix is determined after the volumes of the other reagents are determined. The oligo-dT primer (0.5 μ g/ μ l) is added so that the volume is 10% of the total end volume. The reaction mixture is heated to 70°C for 10 min and then quick-chilled on ice. The following components are added in the order: 5x SUPERSCRIPTM II first strand buffer (20% of total volume); 0.1M DTT (10% of total volume); 10mM dNTP mix (5% of total volume); SUPERSCRIPTM II (5% of total volume). The reaction mixture is centrifuged briefly and then mixed by repeated pipetting. The mixture is incubated at 37°C for 1 hour. 2 μ l of RNase A (10 mg/ml) is then added to the reaction mixture and mixed by pipetting. The reaction mixture is then incubated at 37°C for another hour. At the end of incubation, ddH₂O is added to a final volume of 450 μ l. The cDNA is precipitated by adding 50 μ l of 3M sodium acetate, followed by 1 ml of 100% ethanol. The mixture is then centrifuged for 30 minutes in a microcentrifuge at 12,000 x g. The supernatant is removed and the cDNA resuspended in 100 μ l of ddH₂O. 2 μ l of the resuspended cDNA is then removed and read in a scintillation counter. A total of 1,000,000 cpm is required for hybridization.

The cDNA may be either radiolabelled through the use of α -³²P dCTP (100 μ Ci) in the reaction or chemically labelled through the use of digoxigenin-dUTP using the GENIUS 1 kit (Boehringer Mannheim Biochemical, Indianapolis,

IN).

If an insufficient quantity of stress gene cDNA is obtained by the above process, PCR may be used for amplification. Reverse transcription is carried out as described above, except that no label is incorporated into the cDNA. Primers based on the published 5' and 3' coding sequences of the desired stress gene are used in the PCR reaction.

Amplification of all stress gene cDNAs is carried out in the same reaction tube.

The total cDNA is diluted 1:10 with dH₂O and 10 µl is used for the PCR reaction. The following components are then added to produce the indicated final concentration: 1x TAQ buffer (Boehringer Mannheim Biochemical); 300 µM each dNTP; 25 pmol each PCR primer; 2.5 units TAQ polymerase (Boehringer Mannheim Biochemical); dH₂O to a total reaction volume of 50 µl. The mixture is mixed by pipetting, followed by a second centrifugation. Two drops of light mineral oil are placed on top of the reaction mixture. PCR is set then carried out for 30 cycles of 1 minute at 95°C; 2 minutes at $T_m + 2^\circ\text{C}$; 3 minutes at 72°C (10 minutes during last cycle). The PCR products are labelled with ³²P that has been incorporated into nested primers via a kinase reaction in a one-cycle PCR reaction.

A nested primer is a primer based on a stress specific nucleotide sequence located inside of the sequences upon which the primers for PCR were based. These primers are synthesized using an oligonucleotide synthesizer or purchased from a commercial contractor. The nested primers are labelled by mixing 1.2 µl (0.5 µg/µl) of nested primer with 1.0 µl of 10x kinase buffer (0.5M Tris, pH 8.2, 0.1M MgCl₂, 50 mM DTT); 5.0 µl α-³²P ATP; 1.0 µl polynucleotide kinase and 1.8 µl dH₂O. The reaction is mixed by pipetting and incubated at 37°C for 1 hour. The reaction is terminated by incubation at 70°C for 10 minutes, followed by a quick centrifugation and cooling on ice. 90 µl of dH₂O are then added, followed by 100 µl of phenol/chloroform (1:1). The mixture is mixed well, centrifuged for 10 minutes, and the aqueous phase is then transferred to a new tube. We then precipitate the labelled primers by adding 10 µl of 3M sodium acetate, 1 µl of 10 mg/ml tRNA, and 400 µl of 100% ethanol and placing on ice for 10 minutes. The mixture is then centrifuged for 30 min at room temperature. The pellet is washed with 80% ethanol, centrifuged for 5 seconds and dried. The pellet is resuspended with 4 µl dH₂O, 0.5 µl 10x TAQ buffer, and 0.5 µl TAQ enzyme.

We then add 5 µl of the labeled nested primers to the aqueous phase of the above-described PCR mixture under the mineral oil and perform an additional cycle of PCR by heating to 95°C for 2 minutes, cooling to $T_m + 2^\circ\text{C}$ (of labeled primer) for 2 minutes and warming to 72°C for 10 minutes.

We then remove 50 µl of the aqueous phase to a new tube, add 50 µl dH₂O, 100 µl phenol/chloroform, mix well, and centrifuge for 10 minutes. The aqueous phase is recovered into a fresh tube. Unincorporated primers are removed using a spin column.

4. Hybridization

The membrane containing the cross-linked oligonucleotides is wetted in 15 ml of RAPID HYB buffer (Amersham, Arlington Heights, IL) by holding one end of the membrane with a pair of tweezers and slowly immersing the membrane. The membrane is then prehybridized by transferring to a Seal-a-Meal bag, the 15 ml of RAPID HYB buffer from the wetting step is added, and the bag is sealed. It is then immersed in a 68°C shaking water bath for 1 hour. The labelled cDNA (15,000,000 cpm) is diluted into 1 ml of RAPID HYB and boiled for 10 minutes followed by quick-chilling on ice.

After prehybridization, the RAPID HYB is removed and replaced with 14 ml of fresh RAPID HYB preheated to 65°C. The labelled cDNA is then added to the bag and the end is resealed. The bag is then immersed in a 68°C shaking water bath overnight. After hybridization, the membrane is removed from the bag and placed into a tray containing low stringency buffer (2x SSC/0.1% SDS) for 20 minutes at room temperature. The membrane is then transferred to high stringency buffer (0.2x SSC/0.1% SDS; preheated to 45°C), and shaken for 30 minutes at 45°C. The membrane is then removed from the high stringency wash, placed on a piece of Whatman 3MM filter and exposed to X-ray film at -70°C overnight with an intensifying screen. After development, the autoradiograph is cut to fit into a 96-well microtiter plate holder and taped such that the radioactive dots are aligned with the holes in the holder. The autoradiograph is then read at 600nm for quantification.

The results for either of the two above-described assays are then compared to a database of standards prepared using the above promoters and known toxins. By correlating results for X with known compounds, a toxicity profile can be created. For example, if X induced the same stress genes as TCDD at similar concentrations, this would indicate that X is toxic to whole animals at similar concentrations as TCDD.

EXAMPLE 3

Construction Of Stress Promoter-CAT Fusions

I prepared an XHF promoter-CAT fusion as follows. I synthesized two oligonucleotides based upon the published sequence of the XHF (collagenase) promoter [P Angel et al., *Mol. Cell Biol.*, 7, pp. 2256-66 (1987)]. One corresponded to positions -520 to -501 upstream from the transcription start site primer. [SEQ ID NO 44]: 5'-TACCAGGCAGCT-

TAACAAAG-3'. The other corresponded to positions +53 to +73 downstream from the transcription start site. [SEQ ID NO. 45]: 5'-ACTGGCCTTTGTCTTCTTC-3'. The oligonucleotides were synthesized by Operon Technologies (Alameda, CA). The oligonucleotides were dissolved in water at a final concentration of 500 pmoles/ml.

For XHF promoter amplification I mixed 0.1 µg of Raji (human genomic library) genomic DNA, 20 pmoles of each of the above two primers, 5 µl of 10X buffer [500 mM KCl, 100 mM Tris-HCl, pH 8.3, 15 mM MgCl₂, 0.1% gelatin], 5 µl of 2.0 mM of each dNTP and 1 unit of AMPLITAQ (Taq polymerase) (Perkin-Elmer, Norwalk, CT). I added water to a total volume of 50 µl and performed PCR.

The PCR reaction was run at 94°C for 2 minutes, followed by 30 cycles of: 10 seconds at 56°C, 30 seconds at 71°C and 10 seconds at 94°C. The PCR reaction was completed by incubating the mixture at 56°C for 1.5 minutes followed by 71°C for 4 minutes. The reaction product was then electrophoresed on a 1.0% agarose gel and the amplified sequence excised from the gel and purified. The isolated fragment was then kinased and blunt-end ligated into the pBLCAT3 vector described in B. Luckow et al., *Nucl. Acids Res.*, 15, p. 5490 (1987), the disclosure of which is herein incorporated by reference.

Other stress promoter-CAT fusions may be similarly prepared using any of the above-cited, published nucleotide sequences of the various stress gene promoter regions to design appropriate oligonucleotide primers for PCR. CAT fusions with the following stress promoters were prepared for use in the kits and methods of this invention: XHF, CYP1A1, GST Ya, MTIIA, FOS, HSP70, GADD45, GADD153 and JUN.

EXAMPLE 4

Construction Of A Response Element-CAT Fusion

I constructed a xenobiotic response element XRE-CAT fusion as follows. I first had oligonucleotides corresponding to both strands of the XRE synthesized by an independent contractor (Operon Technologies, Inc., Alameda, CA). The sequence of the XRE is described in M. Denison et al., *J. Biol. Chem.*, 263, pp. 17221-24 (1988). The oligonucleotides were synthesized with overhanging BamHI compatible ends.

The oligonucleotides were dissolved in water at a final concentration of 500 pmoles/ml. I then mixed 50 µg of each oligonucleotide together in a solution containing 500 mM NaCl, 50 mM Tris-HCl, pH 7.8, 1 mM EDTA and boiled for 5 minutes. I then incubated the solution overnight at 68°C to allow the strands to anneal to one another. The double stranded oligos were then electrophoresed on a 12% polyacrylamide gel and purified by excising the band and electroeluting the DNA.

The purified response elements were then kinased and cloned into the BamHI site of pBLCAT2 [M. Denison et al., *J. Biol. Chem.*, 263, pp. 17221-24 (1988)], just upstream of the tk minimal promoter.

Other response element-CAT fusions may be similarly prepared using any of the above-cited, published nucleotide sequences of the various response elements to design appropriate oligonucleotide primers for PCR. CAT fusions with the following response elements were prepared for use in the kits and methods of this invention: XRE, NFkB, CRE, p53RE and RARE.

EXAMPLE 5

Assay Of Toxins Using Stress Promoter-CAT Fusions

Approximately 5×10^4 cells of each of the 14 transformed strains described in Examples 3 and 4 above were separately plated into a row of 12 wells in one of two 96-well plates. An untransformed human liver cell line was plated into the wells of the last row of the second plate to determine cell viability. The cells were grown in 10% Complete Minimal Essential Media (Gibco/BRL, Gaithersburg, MD) at 37°C, 5% CO₂ until reaching 90% confluency.

We tested five or six different concentrations of the various chemicals listed in Table 3, below, dissolved in the appropriate solvent in triplicate.

Table 3

Test Compounds		
Compound	Solvent	Concentration Range
3-MC	DMSO	1 nM - 10µM
Sodium arsenate	water	1 nM - 10µM
DMSO	none	.001 - 10% (v/v)

Table 3 (continued)

Test Compounds		
Compound	Solvent	Concentration Range
Cadmium sulfate	water	100 nM - 10 μ M
Benzo[a]pyrene	DMSO	10 nM - 100 μ M
Ethanol	none	.001 - 10% (v/v)
PMA	ethanol	3.2 - 200 ng/ml
MMS	water	10 ng/ml - 100 μ g/ml
Methapyrilene	water	10 nM - 100 μ M
TCDD	DMSO	1 nM - 10 μ M
Retinoic acid	DMSO	10 nM - 100 μ M

The various concentrations were made by performing a dilution series. For TCDD, we first removed 20 μ l of media from each well in columns 3 through 10 and 10 μ l from columns 11 and 12 of the 96 well plates. We placed 10 μ l of a 200 μ M solution of test chemical into each well in columns 11 and 12. The liquid in those wells was mixed well with a multichannel pipetman using separate pipette tips for each row, and 20 μ l was then transferred from the wells in column 12 to column 10. The liquid in column 10 was mixed and 20 μ l then transferred to column 8 and the procedure repeated for the even numbered columns down to column 4. The same procedure was carried out for the odd numbered columns starting with column 11 and ending with column 3. Columns 1 and 2 of each row represent untreated controls. The plates were then incubated at 37°C, 5% CO₂ overnight.

At the end of the incubation the media was gently aspirated from all of the wells except the cell viability row on the second plate. The cells in all but that last row were washed twice with 200 μ l of phosphate buffered saline. After the wash, we added 100 μ l of Cell Lysis Buffer (5 mM Mops, 2.5 mM NaCl, 0.38 mM MgCl₂, 0.25% Triton X-100, pH to 6.5 using NaOH) to each well and incubated 30 minutes at room temperature. We then combined the lysates in the wells containing duplicate concentrations of chemical by transferring the 100 μ l of lysate in column 12 to column 11, column 10 to column 9, and so on.

We assayed the total protein in each well as follows. In two fresh 96 well plates we added 190 μ l of 1X Protein Assay Reagent (Bio-Rad Laboratories, Hercules, CA) to each well in column 1 through 7. We transferred 10 μ l of cell lysate from the wells in column 1 of the toxin test plate to column 2 of the protein assay plate, from column 3 of the toxin test plate to column 3 of the protein assay plate, from column 5 of the toxin test plate to column 4 of the protein assay plate and so on. The plates were then incubated for 15 minutes at room temperature and then the absorbance of each well read at OD₆₀₀.

The CAT assay was performed using a CAT ELISA kit (5 Prime-3 Prime, Inc., Boulder, CO) and following the manufacturer's directions. We used 190 μ l of each cell lysate in the toxin test plates for determining CAT activity. The CAT assay was allowed to proceed for three and one-half hours at room temperature. CAT activity was measured by using a biotinylated anti-CAT antibody, followed by a streptavidin conjugated alkaline phosphatase, and finally the colorimetric substrate, p-nitrophenyl-phosphate. Color development was measured at OD₄₀₅.

Fold-induction was calculated using the following formula:

$$\frac{OD_{405}(\text{test sample})/OD_{600}(\text{test sample})}{OD_{405}(\text{control})/OD_{600}(\text{control})}$$

The results for each of these experiments is shown graphically in Figures 1 - 11.

EXAMPLE 6

Identification Of Antitoxins

After an unknown compound is found to be a toxin on the basis of its induction of one or more mammalian stress promoters, the same process can be utilized to identify a potential antitoxin.

An unknown compound is demonstrated to induce the HMO promoter and the GADD153 promoter in any of the assays described herein. This indicates that the compound is causing oxidative stress and DNA damage. One possibility

is that the compound is causing hydrogen peroxide formation in sufficiently high amounts to result in DNA strand breaks. Ascorbic acid is known to reduce the number of hydrogen peroxide-induced DNA strand breaks, and therefore is a potential antitoxin to this unknown compound.

HepG2 cells are grown as described in Example 2. The cells are then incubated with varying dilutions of ascorbic acid for 30 minutes. The cells are then exposed to the concentration of unknown compound previously determined to be optimum for inducing the HMO and GADD153 promoters. The assay for promoter induction (and concomitant stress gene expression) is then carried out as described in Example 2. If the ascorbic acid-treated cells produce a lower level of HMO or GADD153 mRNA transcripts than control cells, it is considered to be an antitoxin.

While I have hereinbefore presented a number of embodiments of this invention, it is apparent that my basic construction can be altered to provide other embodiments which utilize the diagnostic kits, processes and products of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: XenometirX, Inc. (all states except US)

2860 Wildemess Place
Suite 150
Boulder, Colorado 80301
United States of America

(i) APPLICANT: Farr, Spencer B (US only)

2852 Kalmia Avenue
No. 184
Boulder, Colorado 80301
United States of America

(i) APPLICANT: Todd, Marque D (US only)

8200 North Sheridan Boulevard
No. 904
Westminster, Colorado 80003
United States of America

(ii) TITLE OF INVENTION: METHODS AND DIAGNOSTIC KITS UTILIZING EUKARYOTIC STRESS PROMOTERS TO DETERMINE TOXICITY OF A COMPOUND

(iii) NUMBER OF SEQUENCES: 45

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: James F. Haley, Jr.
(B) STREET: 1251 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: United States of America
(F) ZIP: 10020

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 08/008,896
- (B) FILING DATE: 21-JAN-1993

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Marks, Andrew S
- (B) REGISTRATION NUMBER: 33,259
- (C) REFERENCE/DOCKET NUMBER: X-1 CIP

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: (212) 596-9000
- (B) TELEFAX: (212) 596-9090
- (C) TELEX: 14-8367

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 70 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AAAAAAAAACCC AGTCCAACCTA CAGACATGGC AGCTGAGTCC CTGCCATTCA CCTTGGAGAC 60
GGTGTTTTTT 70

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 69 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAAAAAGGCC AGTATGCACA GCTTTCCTCC ACTGCTGCTG CTGCTGTTCT GGGGTGTGGT 60
GTCTTTTTTT 69

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 59 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AAAAAACCCC AAGATCCTGA AACAGAGCAT GACCCTGAAC CTGGCCGACC CAGTTTTTTT 59

10

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 63 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AAAAAACAAC CTGAACGTCA ACGAGGAGAA GTACCAGGAG GCGTTGGCCA AGGGAGATTT 60
TTT 63

25

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

30

(A) LENGTH: 60 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

AAAAAATAGA GCGTCCGCAA CCCGACAGCA TGCCCCAGGA TTTGTCAGAG GCCCTTTTTT 60

40

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

45

(A) LENGTH: 65 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AAAAAAGGAG TTGGGAGCTG AGTGGAGAAG AAGCCACGAC TCTCGCTAGG TCAGTACTCT 60
TTTTT 65

55

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 69 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAAAAAGCCG CGGCAGTCGG CATCGACCTG GGCACCACCT ACTCCTGCGT GGGGGTGTTC 60
CAATTTTTTT 69

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAAAAAATTA CAGCAAGCCT GGAACCTATA GCCCCTTTAA CTTGAGCAGC ATCATTTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:9:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
40 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

45 AAAAAACATT CAGGGAAGGG TTGGGTAGGT AGCGAAGAAT AGGGATGAAG TCAGCTTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:10:

50 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
55 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AAAAAAATGC TGGAGAAGGA GTCTGCGGGT GAGTGGTAGT AAGAGAGGCT ATCCCCTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AAAAAAGGAA TCTCATTTTC TAGCTTTGAT CTGGTTGTCA GTTGGGATGG ACTTGCTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AAAAAACCTC TTGCTTCCCC GTGTTGATGT AGCCGAGGAT CTTCTTAAAC TGAGTTTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAAAAACAGT GGTCAATGTC ACGTGGCTTC GAAATGGAAA ACCTGTCACC ACAGGATTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 69 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

AAAAAAGGAT TGTGAAATGA AACGCACCAC ACTGGACAGC CCGTTGGGGA AGCTGGAGCT 60
10 GTCTTTTTT 69

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

AAAAAATTCT TACAATTTTG GTACCACTGC TTGACTAGGC GGATGAGGCT CTTGAGTTTT 60
25 TT 62

(2) INFORMATION FOR SEQ ID NO:16:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
35 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

40 AAAAAAAGTC TTGCATGATC CTTGTCACAA ATAGTTTAAG ATGGCCTGGG TGATTCTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:17:

45 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
50 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

55 AAAAAACCG CACCCCGTCT CCGCGACTAC TTTATAGGCC AGACCTTTT T 51

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

AAAAAAAACC GTACTCTCCC AGTTCTCTTC CATTCCAGA CATCTTGAAT CCACCATTTT 60
TT 62

15

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

AAAAAAGAGT GTCTTTGGCA TACTTGATCA CCAGGCACTT GTACTGAGCA ATCTGGTTTT 60
TT 62

30

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AAAAAAAAC ACCTTCTTCA CATCATCCGC ACTCTTTTTTC TTCAGGCCGA CCATTTTTTT 60
TT 62

45

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AAAAAAGAAG CTCTCAGACA CGAAGTAGAC TGACTGGTAC GTCTGGTCTT GGTAGGTTTT 60
TT 62

5

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

10

- (A) LENGTH: 62 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

AAAAAATCTA GAATATAGGC AGCCAGACCC ACAGGAGAGT CATTGAGACC AGAGCCTTTT 60
TT 62

20

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 62 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

AAAAAAGATA GCGCTCTTCT TCCCACCAAT TCCACTTCTG TTCCTCTTCT TTCTTCTTTT 60
TT 62

35

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 62 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AAAAAAGCCT CTGCCAGTTT TTCTTCAGTC ATCTTCACAA CAAATTTTCAC AGTGGTTTTT 60
TT 62

50

(2) INFORMATION FOR SEQ ID NO:25:

55

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 67 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

AAAAAATCTC TTCCTTGCA GGTGGCTCCTG CACCTGCACT GGCTCCTGCA AATGCAAAGA 60
GTTTTTT 67

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

AATTGCTATG GCGTGGTAAG TGCCCACTGC CCCTTGCTG GATTCAAGAT 50

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

ATCTGAGTTC CTACCTGAAC GGTTTCTCAC CCCTGATGGT GCTATCGACA 50

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

5

GTACTCCCAG CTGCACTGCT TACACGTCTT CCTTCGTCTT CACCT

45

(2) INFORMATION FOR SEQ ID NO:29:

10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

AGGAGAATGA AAGGAAAGTG GCACAGCTAG CTGAAGAGAA TGAACGGCTC

50

25

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

40

AGTCGCTACA TGGATCAATG GGTTCAGTG ATTAATCTCC CTGAACGGTG

50

(2) INFORMATION FOR SEQ ID NO:31:

45

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

GTGGTGGACC TGACCTGCCG TCTAGAAAAA CCTGCCAAAT ATGATGACAT

50

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 50 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CAGCCCAAGG AAGCCTCCCA TGGATGAGAA ATCTTTAGAA GAAGCAAGGA
50

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 44 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CTTACACTCA GCTTTCTGGT GGCGACAGTT GCTGTAGGGC TTTA

44

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

AGAAGGACGA GTTTGAGCAC AAGAGGAAGG AGCTGGAGCA GGTGT

45

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GCTCAGGGAA CAGGTGGCAC AGCTTAAACA GAAAGTCATG AACCACGTTA

50

(2) INFORMATION FOR SEQ ID NO:36:

20

(i) SEQUENCE CHARACTERISTICS:

- 25 (A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

35 GAAAGGCATC TATTTTTTCAA TGGTCAGTGT CCAGGCTGGA ACAAAGCGCC

50

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GCACTGGCTC CTGCAAATGC AAAGAGTGCA AATGCAACTC CTGCAAG

47

55 (2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CCCAGGGCTG CATCTGCAAA GGGGCGTCGG ACAAG

35

15

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: cDNA

25

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

30

ACCACTGTAT TTTGCTCCAA GCAGCCTCTT TGACCTAAAC TTCCAGGCAG

50

(2) INFORMATION FOR SEQ ID NO:40:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

ACAAAAGCCA CTCCACTCTC TTCAACGGTG ACACTCAGTA TGTCTGCAGA

50

50

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

TTGCTCTCGA CAGTATCCAC AATAGCTGAC GGCTGGGTGT TTCAGTTTGA

50

10 (2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 45 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

ACCTTCCAGC AGATGTGGAT TAGCAAGCAG GAGTACGACG AGTCG

45

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 50 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

TTGAGTGGAT CCCCAACAAT GTGAAAACGG CTGTCTGTGA CATCCACCT

50

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

TACCAGGCAG CTTAACAAAC

20

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

ACTGGCCTTT GTCTTCTTTC

20

Claims

1. A diagnostic kit for identifying and characterizing a toxic compound comprising:

(a) a eukaryotic cell characterized by:

- (i) at least one promoter which responds to redox stress;
- (ii) at least one promoter which responds to DNA stress;
- (iii) at least one promoter which responds to protein stress; and
- (iv) at least one promoter responds to energy/ionic stress,

each of said promoters being operatively linked to a different gene which encodes a different detectable product; and

(b) at least four different nucleic acid sequences, each of said nucleic acid sequences being capable of hybridizing to the mRNA transcript of a different one of the genes that is operatively linked to said promoters, or to a single stranded cDNA prepared from said mRNA transcript,

wherein said identification and characterization of said toxic compound is achieved by creating a stress induction profile for said compound.

2. A diagnostic kit for identifying and characterizing a toxic compound comprising:

(a) a eukaryotic cell characterized by at least 4 different promoters which respond to a single category of stress selected from redox stress, DNA stress, protein stress or energy/ionic stress; or a mammalian cell characterized by at least 3 different promoters which respond to cell surface receptor stress; each of said promoters being operatively linked to a gene which encodes a different detectable product; and

(b) the same number of different nucleic acid sequences as there are different promoters in said kit, each of said nucleic acid sequences being capable of hybridizing to the mRNA transcript of a different one of the genes that is operatively linked to each of said promoters, or to a single stranded cDNA prepared from said mRNA transcript,

wherein said identification and characterization of said toxic compound is achieved by creating a stress induction profile for said compound.

3. A diagnostic kit for identifying and characterizing a toxic compound comprising at least:

- (a) a first eukaryotic cell which harbors at least one promoter or response element that responds to redox stress;
- (b) a second eukaryotic cell which harbors at least one promoter or response element that responds to DNA stress;
- (c) a third eukaryotic cell which harbors at least one promoter or response element that responds to protein stress; and
- (d) a fourth eukaryotic cell which harbors at least one promoter or response element that responds to energy/ionic stress;

wherein, each of said promoters or response elements is operatively linked to a heterologous gene encoding a detectable product,

wherein said identification and characterization of said toxic compound is achieved by creating a stress induction profile for said compound.

4. A diagnostic kit for identifying and characterizing a toxic compound comprising

- (a) at least 4 different eukaryotic cells, each of which harbors a different promoter or response element that responds to a single category of stress selected from redox stress, DNA stress, protein stress or energy/ionic stress; or
- (b) at least 3 different mammalian cells, each of which harbors a different promoter or response element that responds to cell surface receptor stress;

wherein each of said promoters is operatively linked to a heterologous gene encoding a detectable product, wherein said identification and characterization of said toxic compound is achieved by creating a stress induction profile for said compound.

5. A method for determining the toxicity of a compound comprising the steps of:

- (a) separately culturing one or more eukaryotic cells which, in toto, are characterized by:

- (i) at least one promoter or response element which responds to redox stress;
- (ii) at least one promoter or response element which responds to DNA stress;
- (iii) at least one promoter or response element which responds to protein stress; and
- (iv) at least one promoter or response element which responds to energy/ionic stress,

each of said promoters or response elements being operatively linked to a gene which encodes a detectable product;

- (b) exposing each of said one or more cultures of cells to said compound;
- (c) quantifying the detectable product in each of said cultures; and
- (d) creating a stress-induction profile for said compound.

6. A method for determining the toxicity of a compound comprising the steps of:

- (a) separately culturing:

- (i) one or more eukaryotic cells which, in toto, are characterized by at least 4 different promoters or response elements that respond to a single category of stress selected from redox stress, DNA stress, protein stress or energy/ionic stress; or
- (ii) one or more mammalian cells which, in toto, are characterized by at least 3 different promoters or response elements that respond to cell surface receptor stress,

wherein each of said promoters or response elements is operatively linked to a gene which encodes a detectable product;

- (b) exposing each of said one or more cultures of cells to said compound;
- (c) quantifying the detectable product in each of said cultures; and
- (d) creating a stress-induction profile for said compound.

7. The diagnostic kit according to claim 2 or 4, or the method according to claim 6, wherein said promoters or response elements respond to redox stress.
- 5 8. The diagnostic kit according to claim 2 or 4, or the method according to claim 6, wherein said promoters or response elements respond to DNA stress.
9. The diagnostic kit according to claim 2 or 4, or the method according to claim 6, wherein said promoters or response elements respond to protein stress.
- 10 10. The diagnostic kit according to claim 2 or 4, or the method according to claim 6, wherein said promoters or response elements respond to energy/ionic stress.
11. The diagnostic kit according to claim 2 or 4, or the method according to claim 6, wherein said promoters or response elements respond to cell surface receptor stress.
- 15 12. The diagnostic kit according to claim 1 or 3, or the method according to claim 5, wherein said diagnostic kit or method is additionally characterized by at least one mammalian cell comprising a promoter that responds to cell surface receptor-mediated stress, wherein said promoter is operatively linked to a gene which encodes a detectable product.
- 20 13. The diagnostic kit according to any one of claims 1 to 4, 7 to 10 or 12, or the method according to any one of claims 5 to 10 or 12, wherein each of said eukaryotic cells is a mammalian cell.
- 25 14. The diagnostic kit according to claim 11 or 13 or the method according to claim 11 or 13, wherein said mammalian cell is a HepG2 cell.
- 30 15. The diagnostic kit according to claim 11 or 12, or the method according to claim 11 or 12, wherein said mammalian cell comprising a promoter that responds to cell surface receptor-mediated stress is a cell derived from the skin or from the eye.
- 35 16. The diagnostic kit according to any one of claims 1 to 4, 7, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 1 to 4, 7 or 12, or the method according to any one of claims 5 to 7, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 5 to 7 or 12, wherein said promoter or response element that responds to redox stress is selected from CYP1A1, GST Ya, JUN, XRE, NFkBRE, RARE, ThRE, PPRE, ERE, NMO1, ALDH1, ALDH2, HMO, MnSOD, UGT, CYP11B2, Cu.ZnSOD, ADPRT, GP, FAOxase, PBE, PPAR, EH, CYP2B2, CYP2E1, CYP3A3, P450b, P450d, PPa, PKC, GST2, GAPDH, NQO or ARE.
- 40 17. The diagnostic kit according to any one of claims 1 to 4, 8, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 1 to 4, 8 or 12, or the method according to any one of claims 5, 6, 8, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 5, 6, 8 or 12, wherein said promoter or response element which responds to DNA stress is selected from GST Ya, GADD45, JUN, FOS, XHF, GADD153, TRE, p53RE, HMO, DRA, MnSOD, MDR-1, EGR-1, GAS 2,3, MGMT, DNA Pol, beta-pol, DHFR, TK, PCNA, PGHS, LOX, ISG15, 2'-5' AS, EH, CYP2E1, TPO1, TPO2, PCNA or PPa.
- 45 18. The diagnostic kit according to any one of claims 1 to 4, 9, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 1 to 4, 9 or 12, or the method according to any one of claims 5, 6, 9, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 5, 6, 9 or 12, wherein said promoter or response element which responds to protein stress is selected from GRP78, JUN, FOS, HSP70, MT 1A, MT IIA, MT III or GP.
- 50 19. The diagnostic kit according to any one of claims 1 to 4, 10, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 1 to 4, 10 or 12, or the method according to any one of claims 5, 6, 10, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 5, 6, 10 or 12, wherein said promoter which responds to energy/ionic stress is selected from GRP78, FOS, CRE, CYP11B2, 2'-5' AS, TH, DBH, ODC, CYP2E1, G6PD, PKC or PVALB.
- 55 20. The diagnostic kit according to any one of claims 1 to 4, 11, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 1 to 4, 11 or 12, or the method according to any one of claims 5, 6, 11, 12 or 13 to 15 insofar as claims 13 to 15 depend from claims 5, 6, 11 or 12, wherein said promoter which responds to cell surface receptor-mediated stress is selected from IL-1 alpha, G-CSF, GM-CSF, TNF alpha, IL-3, IL-8, IL-6, ICAM-1, IL-10 and M-CSF.

21. The diagnostic kit according to claim 1 or the method according to claim 5 wherein:

- (a) said promoters comprise ALDH1, CYP1A1, FOS, GADD153, HMO, HSP70, JUN and MT IIA; and
- (b) said eukaryotic cell is a HepG2 cell.

22. The diagnostic kit according to claim 3, or the method according to claim 5 wherein:

- (a) said promoters or response elements comprise CYP1A1, GST Ya, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE and p53RE; and
- (b) said eukaryotic cells are HepG2 cells.

23. The method according to any one of claims 5 to 22, wherein each of said promoters or response element is in the same cell and wherein quantifying the detectable product comprises the steps of:

- (a) isolating mRNA from said culture exposed to said compound; and
- (b) quantitating the amount of mRNA transcribed from each gene that is operatively linked to each of said stress promoter or response element in said culture.

24. The method according to any one of claims 5 to 22, wherein said gene encoding a detectable product is heterologous to each of said promoters or response elements and wherein each of said promoters or response elements is harbored by a different cell.

25. The diagnostic kit according to any one of claims 3, 4, or 7 to 22 insofar as claims 7 to 22 depend from claim 3 or 4, or the method according to claim 24, wherein each of said promoters or response elements is operatively linked to a gene encoding the same heterologous detectable product.

26. The diagnostic kit according to claim 25 or the method according to claim 24, wherein said heterologous detectable product is CAT.

27. The method according to any one of claims 5 to 26, comprising the additional step of incubating said compound with an S9 liver extract prior to exposing said one or more cultures of cells to said compound.

28. A method of identifying an antitoxin to a new toxic compound comprising the steps of:

- (a) determining the types of stresses caused by said new toxic compound by the method according to any one of claims 5 to 27;
- (b) identifying a known toxic compound which, in the process according to any one of claims 5 - 27, causes stresses similar to those caused by said toxic compound; and
- (c) repeating the method used to determine the types of stresses caused by said new toxic compound according to step (a) with the additional step of treating the eukaryotic cells employed in said method with an antitoxin to said known toxic compound identified in step (b).

29. A method of decreasing the toxicity of a drug, comprising the steps of:

- (a) determining the type of stresses caused by said drug using the methods according to any one of claims 5 to 27; and
- (b) modifying said drug to alter or eliminate the portion thereof suspected of causing said determined stresses.

30. The method according to claim 29, further comprising, after step (b), the additional step of:

- (c) repeating the method used to determine the types of stresses caused by said drug according to step (a) using the modified drug according to step (b).

31. A modified drug produced by the method according to claim 29 or 30.

Patentansprüche

1. Diagnostischer Kit zur Identifizierung und Charakterisierung einer toxischen Verbindung, umfassend

(a) eine eukaryotische Zelle, gekennzeichnet durch:

- (i) mindestens einen Promotor der auf Redoxstreß reagiert;
- (ii) mindestens einen Promotor, der auf DNA-Streß reagiert;
- (iii) mindestens einen Promotor, der auf Proteinstreß reagiert; und
- (iv) mindestens einen Promotor der auf Energie/Ionenstreß reagiert,

wobei die Promotoren mit unterschiedlichen Genen funktionell verbunden sind, die unterschiedliche nachweisbare Produkte codieren; und

(b) mindestens vier verschiedene Nucleinsäuresequenzen, wobei jede der Nucleinsäuresequenzen in der Lage ist, mit dem mRNA-Transkript eines der anderen Gene zu hybridisieren, das funktionell mit den Promotoren verbunden ist, oder mit einer einzelsträngigen cDNA, die von diesem mRNA-Transkript hergestellt worden ist,

wobei die Identifizierung und Charakterisierung der toxischen Verbindung durch die Erzeugung eines Streßinduktionsprofils für die Verbindung erreicht wird.

2. Diagnostischer Kit zur Identifizierung und Charakterisierung einer toxischen Verbindung, umfassend:

(a) eine eukaryotische Zelle, gekennzeichnet durch mindestens vier verschiedene Promotoren, die auf eine einzige Kategorie von Streß reagieren, ausgewählt aus Redoxstreß, DNA-Streß, Proteinstreß oder Energie-/Ionenstreß; oder eine Säugerzelle, gekennzeichnet durch mindestens drei verschiedene Promotoren, die auf Zelloberflächenrezeptorstreß reagieren; wobei jeder der Promotoren mit einem Gen funktionell verbunden ist, das ein anderes nachweisbares Produkt codiert; und

(b) die gleiche Anzahl unterschiedlicher Nucleinsäuresequenzen wie unterschiedliche Promotoren in dem Kit vorhanden sind, wobei die Nucleinsäuresequenzen in der Lage sind, mit dem mRNA-Transkript eines der anderen Gene zu hybridisieren, das funktionell mit jedem der Promotoren verbunden ist; oder zu einer einzelsträngigen cDNA, die von diesem mRNA-Transkript hergestellt wurde,

wobei die Identifizierung und Charakterisierung der toxischen Verbindung durch die Erzeugung eines Streßinduktionsprofils für die Verbindung erreicht wird.

3. Diagnostischer Kit zur Identifizierung und Charakterisierung einer toxischen Verbindung, mindestens umfassend:

- (a) eine erste eukaryotische Zelle, die mindestens einen Promotor oder ein Response-Element trägt, der (das) auf Redoxstreß reagiert;
- (b) eine zweite eukaryotische Zelle, die mindestens einen Promotor oder ein Response-Element trägt, der (das) auf DNA-Streß reagiert;
- (c) eine dritte eukaryotische Zelle, die mindestens einen Promotor oder ein Response-Element trägt, der (das) auf Proteinstreß reagiert; und
- (d) eine vierte eukaryotische Zelle, die mindestens einen Promotor oder ein Response-Element trägt, der (das) auf Energie-/Ionenstreß reagiert;

wobei jeder der Promotoren oder Response-Elemente funktionell mit einem heterologen Gen verbunden ist, das ein nachweisbares Produkt codiert, wobei die Identifizierung und Charakterisierung der toxischen Verbindung durch die Erzeugung eines Streßinduktionsprofils für die Verbindung erreicht wird.

4. Diagnostischer Kit zur Identifizierung und Charakterisierung einer toxischen Verbindung, umfassend:

- (a) mindestens 4 verschiedene eukaryotische Zellen, die jeweils einen unterschiedlichen Promotor oder Response-Element tragen, der (das) auf eine einzige Kategorie von Streß reagiert, ausgewählt aus Redoxstreß, DNA-Streß, Proteinstreß oder Energie-/Ionenstreß, oder
- (b) mindestens 3 verschiedene Säugerzellen, die jeweils einen unterschiedlichen Promotor oder ein Response-Element tragen, der (das) auf Zelloberflächenrezeptorstreß reagiert;

wobei jeder der Promotoren funktionell mit einem heterologen Gen verbunden ist, das ein nachweisbares Produkt codiert,

wobei die Identifizierung und Charakterisierung der toxischen Verbindung durch die Erzeugung eines Streßinduk-

tionsprofils für die Verbindung erreicht wird.

5. Verfahren zur Bestimmung der Toxizität einer Verbindung, umfassend die Schritte:

(a) getrennte Züchtung einer oder mehrerer eukaryotischer Zellen, die insgesamt gekennzeichnet sind durch:

- (i) mindestens einen Promotor oder ein Response-Element, der (das) auf Redoxstreß reagiert;
- (ii) mindestens einen Promotor oder ein Response-Element, der (das) auf DNA-Streß reagiert;
- (iii) mindestens einen Promotor oder ein Response-Element, der (das) auf Proteinstreß reagiert; und
- (iv) mindestens einen Promotor oder ein Response-Element, der (das) auf Energie-/Ionenstreß reagiert,

wobei jeder der Promotoren oder Response-Elemente mit einem Gen funktionell verbunden ist, das ein nachweisbares Produkt codiert;

(b) Aussetzen jeder der einen oder mehreren Zellkulturen der Verbindung;

(c) Quantifizierung des nachweisbaren Produkts in jeder der Kulturen, und

(d) Erzeugung eines Streßinduktionsprofils für die Verbindung.

6. Verfahren zur Bestimmung der Toxizität einer Verbindung, umfassend die Schritte:

(a) getrennte Züchtung:

(i) einer oder mehrerer eukaryotischer Zellen, die insgesamt gekennzeichnet sind durch mindestens 4 verschiedene Promotoren oder Response-Elemente, die auf eine einzige Kategorie von Streß reagieren, ausgewählt aus Redoxstreß, DNA-Streß, Proteinstreß oder Energie-/Ionenstreß; oder

(ii) einer oder mehrerer Säugerzellen, die insgesamt gekennzeichnet sind durch mindestens 3 verschiedene Promotoren oder Response-Elemente, die auf Zelloberflächenrezeptorstreß reagieren,

wobei jeder der Promotoren oder Response-Elemente funktionell mit einem Gen verbunden ist, das ein nachweisbares Produkt codiert;

(b) Aussetzen jeder der einen oder mehreren Zellkulturen der Verbindung;

(c) Quantifizierung des nachweisbaren Produkts in jeder der Kulturen; und

(d) Erzeugung eines Streßinduktionsprofils für die Verbindung.

7. Diagnostischer Kit nach Anspruch 2 oder 4, oder Verfahren nach Anspruch 6, wobei die Promotoren oder Response-Elemente auf Redoxstreß reagieren.

8. Diagnostischer Kit nach Anspruch 2 oder 4, oder Verfahren nach Anspruch 6, wobei die Promotoren oder Response-Elemente auf DNA-Streß reagieren.

9. Diagnostischer Kit nach Anspruch 2 oder 4, oder Verfahren nach Anspruch 6, wobei die Promotoren oder Response-Elemente auf Proteinstreß reagieren.

10. Diagnostischer Kit nach Anspruch 2 oder 4, oder Verfahren nach Anspruch 6, wobei die Promotoren oder Response-Elemente auf Energie-/Ionenstreß reagieren.

11. Diagnostischer Kit nach Anspruch 2 oder 4, oder Verfahren nach Anspruch 6, wobei die Promotoren oder Response-Elemente auf Zelloberflächenrezeptorstreß reagieren.

12. Diagnostischer Kit nach Anspruch 1 oder 3, oder Verfahren nach Anspruch 5, wobei der diagnostische Kit oder das Verfahren zusätzlich gekennzeichnet ist durch mindestens eine Säugerzelle, die einen Promotor umfaßt, der auf Zelloberflächenrezeptor-vermittelten Streß reagiert, wobei der Promotor funktionell mit einem Gen verbunden ist, das ein nachweisbares Produkt codiert.

13. Diagnostischer Kit nach einem der Ansprüche 1 bis 4, 7 bis 10 oder 12, oder Verfahren nach einem der Ansprüche 5 bis 10 oder 12, wobei jede der eukaryotischen Zellen eine Säugerzelle ist.

14. Diagnostischer Kit nach Anspruch 11 oder 13, oder Verfahren nach Anspruch 11 oder 13, wobei die Säugerzelle eine HepG2-Zelle ist.

15. Diagnostischer Kit nach Anspruch 11 oder 12, oder Verfahren nach Anspruch 11 oder 12, wobei die Säugerzelle, die einen Promotor umfaßt, der auf Zelloberflächenrezeptor-vermittelten Streß reagiert, eine Zelle ist, die von der Haut oder vom Auge stammt.

16. Diagnostischer Kit nach einem der Ansprüche 1 bis 4, 7, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 1 bis 4, 7 oder 12, oder Verfahren nach einem der Ansprüche 5 bis 7, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 5 bis 7 oder 12, wobei der Promotor oder das Response-Element, (der) das auf Redoxstreß reagiert, ausgewählt ist aus CYP1A1, GST Ya, JUN, XRE, NFkBRE, RARE, ThRE, PPRE, ERE, NMOI, ALDH1, ALDH2, HMO, MnSOD, UGT, CYP11B2, Cu.ZnSOD, ADPRT, GP, FAOxase, PBE, PPAR, EH, CYP2B2, CYP2E1, CYP3A3, P450b, P450d, PPa, PKC, GST2, GAPDH, NQO oder ARE.

17. Diagnostischer Kit nach einem der Ansprüche 1 bis 4, 8, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 1 bis 4, 8 oder 12, oder Verfahren nach einem der Ansprüche 5, 6, 8, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 5, 6, 8 oder 12, wobei der Promotor oder das Response-Element, der (das) auf DNA-Streß reagiert, ausgewählt ist aus GST Ya, GADD45, JUN, FOS, XHF, GADD153, TRE, p53RE, HMO, DRA, MnSOD, MDR-1, EGR-1, GAS 2,3, MGMT, DNA Pol, beta-pol, DHFR, TK, PCNA, PGHS, LOX, ISG15, 2'-5' AS, EH, CYP2E1, TPO1, TPO2, PCNA oder PPa.

18. Diagnostischer Kit nach einem der Ansprüche 1 bis 4, 9, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 1 bis 4, 9 oder 12, oder Verfahren nach einem der Ansprüche 5, 6, 9, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 5, 6, 9 oder 12, wobei der Promotor oder das Response-Element, der (das) auf Proteinstreß reagiert, ausgewählt ist aus GRP78, JUN, FOS, HSP70, MT 1A, MT IIA, MT III oder GP.

19. Diagnostischer Kit nach einem der Ansprüche 1 bis 4, 10, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 1 bis 4, 10 oder 12, oder Verfahren nach einem der Ansprüche 5, 6, 10, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 5, 6, 10 oder 12, wobei der Promotor, der auf Energie-/Ionenstreß reagiert, ausgewählt ist aus GRP78, FOS, CRE, CYP11B2, 2'-5' AS, TH, DBH, ODC, CYP2E1, G6PD, PKC oder PVALB.

20. Diagnostischer Kit nach einem der Ansprüche 1 bis 4, 11, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 1 bis 4, 11 oder 12, oder Verfahren nach einem der Ansprüche 5, 6, 11, 12 oder 13 bis 15, insoweit die Ansprüche 13 bis 15 abhängig sind von den Ansprüchen 5, 6, 11 oder 12, wobei der Promotor, der auf Zelloberflächenrezeptor-vermittelten Streß reagiert, ausgewählt ist aus IL-1 alpha, G-CSF, GM-CSF, TNF alpha, IL-3, IL-8, IL-6, ICAM-1, IL-10 und M-CSF.

21. Diagnostischer Kit nach Anspruch 1 oder Verfahren nach Anspruch 5, wobei:

- (a) die Promotoren ALDH1, CYP1A1, FOS, GADD153, HMO, HSP70, JUN und MT IIA umfassen; und
- (b) die eukaryotische Zelle eine HepG2-Zelle ist.

22. Diagnostischer Kit nach Anspruch 3, oder Verfahren nach Anspruch 5, wobei:

- (a) die Promotoren oder Response-Elemente CYP1A1, GST Ya, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE und p53RE umfassen; und
- (b) die eukaryotischen Zellen HepG2-Zellen sind.

23. Verfahren nach einem der Ansprüche 5 bis 22, wobei jeder der Promotoren oder Response-Elemente in der gleichen Zelle ist und wobei die Quantifizierung des nachweisbaren Produkts die Schritte umfaßt:

- (a) Isolierung von mRNA aus der Kultur, die der Verbindung ausgesetzt wurde; und
- (b) Quantifizierung der Menge an mRNA, die in der Kultur von jedem Gen transkribiert wurde, das funktionell mit jedem der Streßpromotoren oder Response-Elemente verbunden ist.

24. Verfahren nach einem der Ansprüche 5 bis 22, wobei die Gene, die ein nachweisbares Produkt codieren, heterolog zu jedem der Promotoren oder Response-Elemente sind, und wobei jeder der Promotoren oder Response-Elemente von einer anderen Zelle getragen wird.

25. Diagnostischer Kit nach einem der Ansprüche 3, 4 oder 7 bis 22, insoweit Ansprüche 7 bis 22 abhängig sind von Anspruch 3 oder 4, oder Verfahren nach Anspruch 24, wobei jeder der Promotoren oder Response-Elemente funktionell mit einem Gen verbunden ist, das das gleiche heterologe nachweisbare Produkt codiert.

26. Diagnostischer Kit nach Anspruch 25 oder Verfahren nach Anspruch 24, wobei das heterologe nachweisbare Produkt CAT ist.

27. Verfahren nach einem der Ansprüche 5 bis 26, umfassend den zusätzlichen Schritt der Inkubation der Verbindung mit einem S9-Leberextrakt, bevor eine oder mehrere Zellkulturen der Verbindung ausgesetzt werden.

28. Verfahren zur Identifizierung eines Antitoxins zu einer neuen toxischen Verbindung, umfassend die Schritte:

(a) Bestimmung der Art des Stresses, der durch die neue toxische Verbindung verursacht wird, unter Verwendung des Verfahrens nach einem der Ansprüche 5 bis 27;

(b) Identifizierung einer bekannten toxischen Verbindung, die in dem Verfahren nach einem der Ansprüche 5 bis 27, einen Streß verursacht, der ähnlich ist zu dem, der durch die toxische Verbindung verursacht wird; und

(c) Wiederholung des Verfahrens, das zur Bestimmung der Art des Stresses benutzt wurde, der durch die neue toxische Verbindung verursacht wird, gemäß Schritt (a) mit dem zusätzlichen Schritt der Behandlung der in diesem Verfahren benutzten eukaryotischen Zellen mit einem Antitoxin zu der bekannten toxischen Verbindung, die in Schritt (b) identifiziert wurde.

29. Verfahren zur Verminderung der Toxizität eines Wirkstoffs, umfassend die Schritte:

(a) Bestimmung der Art des Stresses, die durch den Wirkstoff verursacht wird, unter Verwendung des Verfahrens nach einem der Ansprüche 5 bis 27; und

(b) Modifizierung des Wirkstoffs, um den Teil zu verändern oder zu beseitigen, von dem man annimmt, daß er den festgestellten Streß verursacht.

30. Verfahren nach Anspruch 29, weiterhin umfassend, nach Schritt (b) den zusätzlichen Schritt:

(c) Wiederholung des Verfahrens, das zur Bestimmung der Art des Stresses benutzt wurde, der durch den Wirkstoff verursacht wird, gemäß Schritt (a) unter Verwendung des modifizierten Wirkstoffs gemäß Schritt (b).

31. Modifizierter Wirkstoff, der durch das Verfahren nach Anspruch 29 oder 30 hergestellt wird.

Revendications

1. Kit de diagnostic pour identifier et caractériser un composé toxique comprenant :

(a) une cellule eucaryotique caractérisée par :

(i) au moins un promoteur qui répond à une contrainte rédox ;

(ii) au moins un promoteur qui répond à une contrainte d'ADN ;

(iii) au moins un promoteur qui répond à une contrainte de protéine; et

(iv) au moins un promoteur qui répond à une contrainte d'énergie/ionique,

chacun desdits promoteurs étant opérationnellement ponté à un gène différent qui encode un produit détectable différent ; et

(b) au moins quatre séquences d'acide nucléique différentes, chacune desdites séquences d'acide nucléique étant capable d'hybrider au transcript d'ARNm de l'un différent des gènes qui est opérationnellement ponté auxdits promoteurs, ou à un ADNc unique préparé à partir dudit transcript d'ARNm,

où lesdites identification et caractérisation dudit composé toxique sont atteintes en créant un profil d'induction de contraintes pour ledit composé.

2. Kit de diagnostic pour identifier et caractériser un composé toxique comprenant :

(a) une cellule eucaryotique caractérisée par au moins quatre promoteurs différents qui répondent à une ca-

tégorie unique de contraintes choisies parmi une contrainte de rédox, une contrainte d'ADN, une contrainte de protéine ou une contrainte d'énergie/ionique ; ou une cellule mammalienne caractérisée par au moins trois promoteurs différents qui répondent à une contrainte d'un récepteur de surface de cellule ; chacun desdits promoteurs étant opérationnellement ponté à un gène qui encode un produit détectable différent ; et

(b) le même nombre de séquences d'acide nucléique différentes qu'il y a de promoteurs différents dans ledit kit, chacune desdites séquences d'acide nucléique étant capable d'hybrider au transcript d'ARNm de l'un différent des gènes qui est opérationnellement ponté à chacun desdits promoteurs, ou à un ADNc à brin unique préparé à partir dudit transcript d'ARNm,

où ladite identification et ladite caractérisation dudit composé toxique sont atteintes en créant un profil d'induction de contraintes pour ledit composé.

3. Kit de diagnostic pour identifier et caractériser un composé toxique comprenant au moins :

(a) une première cellule eucaryotique qui abrite au moins un promoteur ou un élément de réponse qui répond à une contrainte de rédox ;

(b) une seconde cellule eucaryotique qui abrite au moins un promoteur ou un élément de réponse qui répond à une contrainte d'ADN ;

(c) une troisième cellule eucaryotique qui abrite au moins un promoteur ou un élément de réponse qui répond à une contrainte de protéine ; et

(d) une quatrième cellule eucaryotique qui abrite au moins un promoteur ou un élément de réponse qui répond à une contrainte d'énergie/ionique ; où, chacun desdits promoteurs ou desdits éléments de réponse est opérationnellement ponté à un gène hétérologue encodant un produit détectable,

où ladite identification et ladite caractérisation dudit composé toxique sont atteintes en créant un profil d'induction de contraintes pour ledit composé.

4. Kit de diagnostic pour identifier et caractériser un composé toxique comprenant

(a) au moins quatre cellules eucaryotiques différentes, qui chacune abrite un promoteur ou un élément de réponse différent qui répond à une catégorie unique de contraintes sélectionnées parmi une contrainte rédox, une contrainte d'ADN, une contrainte de protéine ou une contrainte d'énergie/ionique ; ou

(b) au moins trois cellules mammaliennes différentes, qui chacune abrite un promoteur différent ou un élément de réponse différent qui répond à une contrainte de récepteur de surface des cellules ;

où chacun desdits promoteurs est opérationnellement ponté à un gène-hétérologue encodant un produit détectable, où ladite identification et ladite caractérisation dudit composé toxique sont atteintes en créant un profil d'induction de contraintes pour ledit composé.

5. Méthode pour déterminer la toxicité d'un composé comprenant les étapes de :

(a) culture séparément d'une ou plus cellules eucaryotiques qui, en bloc, sont caractérisées par :

(i) au moins un promoteur ou élément de réponse qui répond à une contrainte rédox ;

(ii) au moins un promoteur ou un élément de réponse qui répond à une contrainte d'ADN ;

(iii) au moins un promoteur ou élément de réponse qui répond à une contrainte de protéine ; et

(iv) au moins un promoteur ou élément de réponse qui répond à une contrainte d'énergie/ionique,

chacun desdits promoteurs ou éléments de réponse étant opérationnellement ponté à un gène qui encode un produit détectable ;

(b) exposition de chacune desdites une ou plusieurs cultures des cellules audit composé ;

(c) quantification du produit détectable dans chacune desdites cultures ; et

(d) création d'un profil d'induction de contraintes pour ledit composé.

6. Méthode pour déterminer la toxicité d'un composé comprenant les étapes de :

(a) culture séparément :

(i) d'une ou plus cellules eucaryotiques qui, en bloc, sont caractérisées par au moins quatre promoteurs ou éléments de réponse différents qui répondent à une catégorie unique de contraintes sélectionnées parmi une contrainte rédox, une contrainte d'ADN, une contrainte de protéine ou contrainte d'énergie/ionique ; ou

(ii) une ou plus cellules mammaliennes qui, en bloc, sont caractérisées par au moins trois promoteurs ou éléments de réponse différents qui répondent à une contrainte de récepteur de surface de cellule,

où chacun desdits promoteurs ou éléments de réponse est opérationnellement ponté à un gène qui encode un produit détectable ;

(b) exposition de chacune desdites une ou plus cultures de cellules audit composé ;

(c) quantification du produit détectable dans chacune desdites cultures ;

(d) création d'un profil d'induction de contraintes pour ledit composé.

7. Kit de diagnostic selon la revendication 2 ou 4, ou méthode selon la revendication 6, dans lesquels lesdits promoteurs ou éléments de réponse répondent à une contrainte rédox.

8. Kit de diagnostic selon la revendication 2 ou 4, ou méthode selon la revendication 6, dans lesquels lesdits promoteurs ou éléments de réponse répondent à une contrainte d'ADN.

9. Kit de diagnostic selon la revendication 2 ou 4, ou méthode selon la revendication 6, dans lesquels ledit promoteur ou élément de réponse répond à une contrainte de protéine.

10. Kit de diagnostic selon la revendication 2 ou 4, ou méthode selon la revendication 6, dans lesquels lesdits promoteurs ou éléments de réponse répondent à une contrainte d'énergie/ionique.

11. Kit de diagnostic selon la revendication 2 ou 4, méthode selon 6, dans lesquels lesdits promoteurs ou éléments de réponse répondent à une contrainte de récepteur de surface de cellule.

12. Kit de diagnostic selon la revendication 1 ou 3, ou méthode selon la revendication 5, dans lesquels ledit diagnostic ou ladite méthode sont additionnellement caractérisés par au moins une cellule mammalienne comprenant un promoteur qui répond à une contrainte médiatée par un récepteur de surface de cellule, où ledit promoteur est ponté opérationnellement à un gène qui encode un produit détectable.

13. Kit de diagnostic selon l'une quelconque des revendications 1 à 4, 7 à 10 ou 12, ou méthode selon l'une quelconque des revendications 5 à 10 ou 12, où chacune desdites cellules eucaryotiques est une cellule mammalienne.

14. Kit de diagnostic selon la revendication 11 ou 13 ou méthode selon la revendication 11 ou 13, où ladite cellule mammalienne est une cellule HepG2.

15. Kit de diagnostic selon la revendication 11 ou 12, ou méthode selon la revendication 11 ou 12, où ladite cellule mammalienne comprenant un promoteur qui répond à une contrainte médiatée par un récepteur de surface de cellule est une cellule dérivée de la peau ou de l'oeil.

16. Kit de diagnostic selon l'une quelconque des revendications 1 à 4, 7, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 1 à 4, 7 ou 12, ou méthode selon l'une quelconque des revendications 5 à 7, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 5 à 7 ou 12, où ledit promoteur ou élément de réponse qui répond à une contrainte rédox est choisi parmi CYP1A1, GST Ya, JUN, XRE, NFkBRE, RARE, ThRE, PPRE, ERE, NMO1, ALDH1, ALDH2, HMO, MnSOD, UGT, CYP11B2, Cu.ZnSOD, ADPRT, GP, FAOxase, PBE, PPAR, EH, CYP2B2, CYP2E1, CYP3A3, P450b, P450d, PPa, PKC, GST2, GAPDH, NQO ou ARE.

17. Kit de diagnostic selon l'une quelconque des revendications 1 à 4, 8, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 1 à 4, 8 ou 12, ou méthode selon l'une quelconque des revendications 5, 6, 8, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 5, 6, 8 ou 12, où ledit promoteur ou élément de réponse qui répond à une contrainte d'ADN est choisi parmi GST Ya, GADD45, JUN, FOS, XHF, GADD153, TRE, p53RE, HMO, DRA, MnSOD, MDR-1, EGR-1, GAS 2,3, MGMT, ADN Pol, beta-pol, DHFR, TK, PCNA, PGHS, LOX, ISG15, 2'-5' AS, EH, CYP2E1, TPO1, TPO2, PCNA ou PPa.

18. Kit de diagnostic selon l'une quelconque des revendications 1 à 4, 9, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 1 à 4, 9 ou 12, ou méthode selon l'une quelconque des revendications 5, 6, 9, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 5, 6, 9 ou 12, où ledit promoteur ou ledit élément de réponse qui répond à une contrainte de protéine est choisi parmi GRP78, JUN, FOS, HSP70, MT 1A, MT IIA, MT III ou GP.
19. Kit de diagnostic selon l'une quelconque des revendications 1 à 4, 10, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 1 à 4, 10 ou 12, ou méthode selon l'une quelconque des revendications 5, 6, 10, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 5, 6, 10 ou 12, où ledit promoteur qui répond à une contrainte d'énergie/ionique est choisi parmi GRP78, FOS, CRE, CYP11B2, 2'-5' AS, TH, DBH, ODC, CYP2E1, G6PD, PKC ou PVALB.
20. Kit de diagnostic selon l'une quelconque des revendications 1 à 4, 11, 12 ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 1 à 4, 11 ou 12, ou méthode selon l'une quelconque des revendications 5, 6, 11, 12, ou 13 à 15 dans la mesure où les revendications 13 à 15 dépendent des revendications 5, 6, 11 ou 12, où ledit promoteur qui répond à une contrainte médiatée par le récepteur de surface de cellule est sélectionné parmi IL-1 alpha, G-CSF, GM-CSF, TNF alpha, IL-3, IL-8, IL-6, ICAM-1, IL-10 et M-CSF.
21. Kit de diagnostic selon la revendication 1 ou méthode selon la revendication 5 où :
 - (a) lesdits promoteurs comprennent ALDH1, CYP1A1, FOS, GADD153, HMO, HSP70, JUN et MT IIA ; et
 - (b) ladite cellule eucaryotique est une cellule HepG2.
22. Kit de diagnostic selon la revendication 3, ou méthode selon la revendication 5 où :
 - (a) lesdits promoteurs ou éléments de réponse comprennent CYP1A1, GST Ya, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE et p53RE ; et
 - (b) lesdites cellules eucaryotiques sont des cellules HepG2.
23. Méthode selon l'une quelconque des revendications 5 à 22, où chacun desdits promoteurs ou éléments de réponse est dans la même cellule et où la quantification du produit détectable comprend les étapes de :
 - (a) isolement de l'ARNm de ladite culture exposée audit composé ; et
 - (b) quantification de la quantité d'ARNm transcrite à partir de chaque gène qui y est opérationnellement ponté à chacun desdits promoteurs ou éléments de réponse de contrainte dans ladite culture.
24. Méthode selon l'une quelconque des revendications 5 à 22, où ledit gène encodant un produit détectable est hétérologue à chacun desdits promoteurs ou éléments de réponse et où chacun desdits promoteurs ou éléments de réponse est créé par une cellule différente.
25. Kit de diagnostic selon l'une quelconque des revendications 3, 4, ou 7 à 22 dans la mesure où les revendications 7 à 22 dépendent de la revendication 3 ou 4, ou méthode selon la revendication 24, où chacun des promoteurs ou éléments de réponse est opérationnellement ponté à un gène encodant le même produit détectable hétérologue.
26. Kit de diagnostic selon la revendication 25 ou méthode selon la revendication 24 où ledit produit détectable hétérologue est CAT.
27. Méthode selon l'une quelconque des revendications 5 à 26, comprenant l'étape additionnelle d'incubation dudit composé avec un extrait de foie S9 avant exposition desdites une ou plus cultures de cellules audit composé.
28. Méthode d'identification d'une antitoxine à un nouveau composé toxique comprenant les étapes de :
 - (a) détermination des types de contraintes provoquées par ledit nouveau composé toxique par la méthode selon l'une quelconque des revendications 5 à 27 ;
 - (b) identification d'un composé toxique connu qui, dans le procédé selon l'une quelconque des revendications 5 à 27, provoque des contraintes similaires à celles provoquées par ledit composé toxique ; et
 - (c) répétition de la méthode utilisée pour déterminer les types de contraintes provoquées par ledit nouveau composé toxique selon l'étape (a) avec l'étape additionnelle de traitement des cellules eucaryotiques em-

ployées dans ladite méthode avec une antitoxine audit composé toxique connu identifié dans l'étape (b).

29. Méthode de diminution de la toxicité d'un médicament, comprenant les étapes de :

- 5 (a) détermination du type de contraintes provoquées par les médicaments en utilisant les méthodes selon l'une quelconque des revendications 5 à 27 ; et
 (b) modification dudit médicament pour altérer ou éliminer la portion de celui-ci suspectée de provoquer les-dites contraintes déterminées.

- 10 30. Méthode selon la revendication 29, comprenant de plus, après l'étape (b), l'étape additionnelle de :
 (c) répétition de la méthode utilisée pour déterminer les types de contraintes provoquées par ledit médicament selon l'étape (a) en utilisant le médicament modifié selon l'étape (b).

15 31. Médicament modifié produit par la méthode selon la revendication 29 ou 30.

15

20

25

30

35

40

45

50

55


FIGURE 1

FIGURE 2

3-Methyl cholanthrene




FIGURE 3

Benzo(a)pyrene




FIGURE 4

Cadmium Sulfate




FIGURE 5

DMSO




FIGURE 6

Ethanol




FIGURE 7

Methapyrilene hydrochloride




FIGURE 8

Methanesulfonic Acid Methyl (MMS)




FIGURE 9

Sodium Arsenate




FIGURE 10

PMA




FIGURE 11

All Trans Retinoic Acid

